 |
| Date | Title | | | 09/03/09 | Meridian Bioscience to Present at the Robert W. Baird 2009 Health Care Conference| CINCINNATI--(BUSINESS WIRE)--Sep. 3, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that the Company has been invited to present at the Robert W.
Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at
1:45 p.m. ET at the Four Seasons Hotel New York. Jack Kraeutler, Chief
Executive Officer, and Bill Motto, Executive Chairman of the Board, are
scheduled to present. A question and answer session will foll... |
|  | | 07/16/09 | Meridian Bioscience Appoints James M. Anderson to Board of Directors| CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has appointed James M. Anderson to its Board of
Directors effective immediately.
Mr. Anderson is President and Chief Executive Officer of Cincinnati
Children’s Hospital Medical Center. His appointment as President and CEO
in 1996 followed 20 years of service to the Cincinnati Children’s board
of ... |
| | | 07/16/09 | Meridian Bioscience Reports Record Sales and Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2009 Guidance, and Comments on Timing of Fiscal 2010 Guidance| CINCINNATI--(BUSINESS WIRE)--Jul. 16, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record quarterly and nine-month sales of $38.2 million and
$105.8 million, respectively, increases of 16% and 3% over the same
periods of the prior fiscal year;
reported record quarterly and nine-month operating income of $12.5
million and $35.7 million, respectively, increases of 14% and
... |
| | | 07/07/09 | FORTUNE Small Business Again Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies| CINCINNATI--(BUSINESS WIRE)--Jul. 7, 2009--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced
today that FORTUNE Small Business has ranked Meridian Bioscience, Inc.
number 34 on their ninth annual FSB 100 list of the fastest growing
small public companies in America. The list appears in the July/August
issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2009/.
To compile th... |
| | | 06/10/09 | Meridian Bioscience to Present at the William Blair and Company's 29th Annual Growth Stock Conference| CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that the
Company has been invited to present at the William Blair and Company’s 29th
Annual Growth Stock Conference on Thursday, June 11 at 9:20 a.m. CDT at
the Four Seasons Hotel, Chicago, IL. Jack Kraeutler, Chief Executive
Officer, and Bill Motto, Executive Chairman of the Board, are scheduled
to present. A question and answer session will f... |
| | | 06/04/09 | Meridian Bioscience Wins GHX 2009 Best in Class Award| CINCINNATI--(BUSINESS WIRE)--Jun. 4, 2009--
Meridian Bioscience (NASDAQ: VIVO) today announced that it is a
recipient of a 2009 GHX Best in Class Award for achieving the highest
year-over-year market share growth for distributed products in the
Microbiology Reagents/Supplies product category for the 2008 calendar
year.
Meridian Bioscience was among the 30 leading medical-surgical product
manufacturers recognized by GHX in five market... |
| | | 06/03/09 | Meridian Bioscience Receives FDA Clearance for New Rapid Campylobacter Test| CINCINNATI--(BUSINESS WIRE)--Jun. 3, 2009--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has
received FDA clearance from the U.S. Food and Drug Administration (FDA)
for a new rapid test for Campylobacter, ImmunoCard STAT!®
CAMPY. This new test provides fast and accurate detection of Campylobacter
bacteria, one of the most common causes of diarrheal illness and the
most common bacterial cause of foodborne illness in the United Stat... |
| | | 04/16/09 | Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Revises Downward Fiscal 2009 Guidance| CINCINNATI, Apr 16, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported second quarter and six months net sales of $33.3 million and
$67.6 million, respectively, decreases of 8% and 4% compared to the
same periods of the prior fiscal year;
reported second quarter and six months operating income of $11.0
million and $23.2 m... |
| | | 02/04/09 | Meridian Bioscience Receives FDA Clearance for New Campylobacter Test| CINCINNATI--(BUSINESS WIRE)--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has
received FDA clearance from the U.S. Food and Drug Administration (FDA)
for a new test for Campylobacter. Launched as PREMIER™ CAMPY, the rapid
EIA test provides for optimized detection of Campylobacter infection,
the most commonly diagnosed bacteria for food borne illness in the U.S.
Approximately 20 million tests are conducted each year in the U... |
| | | 01/27/09 | Meridian Bioscience Announces Two New Exclusive International Distribution Agreements in Australia and Argentina| CINCINNATI, Jan 27, 2009 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced the commencement of two new exclusive international
distribution agreements. In Australia, Meridian has signed with Immuno
Pty, Ltd, based in Sydney. For Argentina, Meridian has signed with Scott
Pharma. This decision is consistent with Meridian's stated commitment to
expand its non-US businesses.
Over the past 25 years Immuno Pty, www.im... |
| | | 01/22/09 | Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2009 Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2009--Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
-- reported record first quarter net sales of $34.3 million a 1% increase
over the same period of the prior fiscal year;
-- reported record first quarter net earnings of $8.1 million, an 8%
increase over the same period of the prior fiscal year;
-- re... |
| | | 01/15/09 | Meridian Bioscience, Inc. Announces Preliminary First Quarter Operating Results and Revises Fiscal 2009 Revenue Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2009--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that based on preliminary results, it expects revenues for the
first quarter of fiscal 2009, ended on December 31, 2008, to be
approximately $34,300,000, an increase of 1% over the prior year. During
the quarter, sales to our largest distributor were essentially flat.
However, shipments to customers from this distributor continued at a
... |
| | | 12/10/08 | Meridian Bioscience to Participate in Panel Presentation at RBC Capital Markets 2008 Healthcare Conference| CINCINNATI--(BUSINESS WIRE)--Dec. 10, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that Jack Kraeutler, Chief Executive Officer, will be
presenting as a panel participant at the RBC Capital Markets 2008
Healthcare Conference, held at the Westin Times Square Hotel in New
York. The panel titled, Getting to the Point (of Care) is
scheduled from 9-9:55 a.m. ET. on December 11, 2008 in Panel Room 2. The
information prov... |
| | | 12/02/08 | Meridian Bioscience Announces Filing of Shelf Registration Statement to Replace Expiring Registration Statement| CINCINNATI--(BUSINESS WIRE)--Dec. 2, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today
announced it has filed a shelf registration statement on Form S-3 with
the US Securities and Exchange Commission. This registration statement
replaces the Company's existing shelf registration statement originally
filed in September 2003 which was scheduled to expire on December 1,
2008. This unlimited shelf registration includes common stock, preferre... |
| | | 11/17/08 | Meridian Bioscience to Present at theLazard Capital Markets 5th Annual Healthcare Conference| CINCINNATI, Nov 17, 2008 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that the Company has been invited to present at the Lazard
Capital Markets 5th Annual Healthcare Conference on Tuesday,
November 18, 2008 at 8:55 a.m. ET at The St. Regis, New York. Melissa
Lueke, Vice President, CFO, is scheduled to present. A question and
answer session will follow the Company's presentation. The information
prov... |
| | | 11/12/08 | Meridian Bioscience Reports Record Fiscal 2008 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2008--Meridian Bioscience,
Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record fourth quarter and full-year fiscal 2008 net
sales of $36.5 million and $139.6 million, respectively,
increases of 13% and 14%, respectively, over the same periods
of the prior fiscal year;
reported record fourth quarter and full-year fiscal 2008
... |
| | | 10/30/08 | New Molecular Test for C. difficile from Meridian Bioscience Expected to be Launched in Fiscal Year 2009| CINCINNATI--(BUSINESS WIRE)--Oct. 30, 2008--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced, in conjunction
with the Association for Molecular Pathology 2008 Annual Meeting now
occurring in Grapevine, Texas, that it anticipates launching a simple,
rapid new molecular test for the toxin-producing forms of the C.
difficile bacteria in the second half of fiscal year 2009. This
innovative molecular test is based upon Loop Mediated Isothermal
Amplification (LAMP)... |
| | | 10/01/08 | Meridian Bioscience to Present at the William Blair and Company Small-Cap Growth Stock Conference| CINCINNATI--(BUSINESS WIRE)--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that the Company has been invited to present at the William
Blair and Company Small-Cap Growth Stock Conference on Tuesday,
October 7, 2008 at 12:00 p.m. ET at the Waldorf-Astoria Hotel, New
York. Jack Kraeutler, Chief Executive Officer, is scheduled to
present. A question and answer session will follow the Company's
presentation. The information provided during the session may n... |
| | | 09/23/08 | Meridian Bioscience to Present at the 2008 UBS Global Life Science Conference| CINCINNATI, Sep 23, 2008 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that the Company has been invited to present at the 2008 UBS
Global Life Science Conference at the Grand Hyatt New York in New York
City. Jack Kraeutler, CEO, is scheduled to present on Wednesday,
September 24, 2008 at 1:30 p.m. ET. A question and answer session will
follow and some of the information provided during the session may not
... |
| | | 09/10/08 | Meridian Bioscience Announces New Exclusive Canadian Distribution Agreement with Somagen Diagnostics| CINCINNATI--(BUSINESS WIRE)--Sept. 10, 2008--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the commencement
of a new exclusive Canadian distribution agreement with Somagen
Diagnostics, Edmonton, Alberta. This decision is consistent with
Meridian's stated commitment to expand its non-US businesses.
Somagen Diagnostics, www.somagen.com, focuses on niche markets
within the clinical diagnostic market. Like Meridian, Somagen targets
markets where they can... |
| | | 09/05/08 | Meridian Bioscience to Present at the Robert W. Baird 2008 Small Cap Healthcare Conference| CINCINNATI--(BUSINESS WIRE)--Sept. 5, 2008--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company
has been invited to present at the Robert W. Baird 2008 Small Cap
Healthcare Conference on Wednesday, September 10, 2008 at 12:50 p.m.
ET at the Intercontinental The Barclay New York. Jack Kraeutler, Chief
Executive Officer, is scheduled to present. A question and answer
session will follow the Company's presentation. The information
provided during t... |
| | | 08/14/08 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2009 and Reaffirms Fiscal 2008 Guidance| CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2008--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial
community with guidance regarding the Company's fiscal 2009 sales and
earnings estimates. Based on the Company's business planning and
budgeting activities for the fiscal year ending September 30, 2009,
management expects net sales to be in the range of $157 to $160
million and per share diluted earnings to be between $0.86 and $0.90.
The per share estima... |
| | | 07/17/08 | Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2008 Guidance, and Comments on Fiscal 2009 Outlook| CINCINNATI--(BUSINESS WIRE)--July 17, 2008--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
-- reported record third quarter and nine-month sales of $33.1
million and $103.2 million, respectively, increases of 11% and
14% over the same periods of the prior fiscal year;
-- reported record third quarter and nine-month operating income
of $11.0 million and $32.9 million, respectively, increases of
16% and 25% over the same... |
| | | 06/25/08 | Fortune Small Business Lists Meridian Bioscience as One of America's Fastest-Growing Small Companies| CINCINNATI, June 25, 2008 (PRIME NEWSWIRE) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that FORTUNE Small Business has ranked Meridian Bioscience, Inc. number 65 on its eighth annual FSB 100 list of the fastest-growing small public companies in America. The list appears in the July/August issue of FORTUNE Small Business and is available online at http://money.cnn.com/magazines/fsb/fsb100/2008/
John A. Kraeutler, Chief Executive Officer, stated, The development, manufacture an... |
| | | 06/19/08 | Meridian Bioscience Completes Acquisition of Recombinant Protein Technologies and Products from Vybion, Inc.| CINCINNATI--(BUSINESS WIRE)--June 19, 2008--Meridian Bioscience,
Inc. (NASDAQ: VIVO) today announced it has completed the purchase of
technologies and products including infectious disease recombinant
proteins and cardiac antigens from Vybion, Inc., highlights include:
-- year 1 revenues of approximately $400,000 with attractive
margins post-integration;
-- purchase price of $653,000 in cash plus future royalties based
on net sales of the acquired product... |
| | | 05/13/08 | Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc.| CINCINNATI--(BUSINESS WIRE)--May 13, 2008--Meridian Bioscience,
Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a
letter of intent to acquire a line of infectious disease recombinant
proteins and cardiac antigens from Vybion, Inc. The purchase price
includes cash and future royalties based on net sales of the acquired
products, the amounts of which were not disclosed. The assets to be
acquired include a portfolio of recombinant viral proteins and cardiac
antigens,... |
| | | 05/12/08 | Meridian Bioscience to Present At the Nasdaq 21st Investor Program, London| CINCINNATI, May 12, 2008 (PrimeNewswire via COMTEX News Network) -- Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that the Company has been invited to present at the NASDAQ 21st Investor Program, London on Wednesday, May 21, 2008 at 11:15 a.m. BST at The Andaz Hotel, London, UK. Bill Motto, Executive Chairman of the Board and Jack Kraeutler, Chief Executive Officer, are scheduled to present. A question and answer session will follow the Company's presentation. The information provided ... |
| | | 05/12/08 | Meridian Bioscience to Present at the Robert W. Baird 2008 Growth Stock Conference| CINCINNATI--(BUSINESS WIRE)--May 12, 2008--Meridian Bioscience,
Inc. (NASDAQ: VIVO) today announced that the Company has been invited
to present at the Robert W. Baird 2008 Growth Stock Conference on
Wednesday, May 14, 2008 at 3:05 p.m. CDT at the Four Seasons Hotel in
Chicago. Bill Motto, Executive Chairman of the Board and Jack
Kraeutler, Chief Executive Officer, are scheduled to present. A
question and answer session will follow the Company's presentation.
The information provided ... |
| | | 04/17/08 | Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results| CINCINNATI--(BUSINESS WIRE)--April 17, 2008--Meridian Bioscience,
Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
-- reported record second quarter and six months net sales of
$36.2 million and $70.1 million, respectively, increases of
13% and 15% over the same periods of the prior fiscal year;
-- reported record second quarter and six months net earnings of
$7.3 million and ... |
| | | 04/09/08 | Meridian Bioscience Launches Two New TRU(TM) Brand Rapid Tests for the Detection of Epstein-Barr Virus| CINCINNATI--(BUSINESS WIRE)--April 9, 2008--Meridian Bioscience,
Inc. (NASDAQ: VIVO) today announced that it has launched two new rapid
tests for Epstein-Barr Virus (EBV): TRU EBV-M(TM) and TRU EBV-G(TM).
The TRU EBV tests are the first rapid tests on the market which employ
recombinant antigen technology to detect IgM and IgG antibodies
specific to EBV.
EBV is the primary cause of infectious mononucleosis and has been
implicated in a number of benign and malignant disorders, incl... |
| | | 03/25/08 | Meridian Bioscience to Present at the Sidoti & Company, LLC Twelfth Annual New York Emerging Growth Institutional Investor Forum| CINCINNATI--(BUSINESS WIRE)--March 25, 2008--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Company
has been invited to present at the Sidoti & Company, LLC Twelfth
Annual New York Emerging Growth Institutional Investor Forum at The
Hyatt Regency Hotel in New York. Jack Kraeutler, Chief Executive
Officer, is scheduled to present on Wednesday, March, 26, 2008 at 1:30
p.m. ET. A question and answer session will follow and some of the
information prov... |
| | | 01/28/08 | Meridian Bioscience Promotes John A. Kraeutler to Chief Executive Officer, William J. Motto Moves to Executive Chairman| CINCINNATI--(BUSINESS WIRE)--Jan. 28, 2008--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that the Board
of Directors has appointed Jack Kraeutler to Chief Executive Officer.
Mr. Kraeutler joined the Company in January, 1992 as Executive Vice
President and Chief Operating Officer. In July 1992, Mr. Kraeutler was
named President and Chief Operating Officer of Meridian. Before
joining Meridian, Mr. Kraeutler served as Vice President, General
Manager for a di... |
| | | 01/22/08 | Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2008 Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2008--Meridian Bioscience,
Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
----------------------------------------------------------------------
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
-- reported record first quarter net sales of $33.8 million an
18% increase over the same period of the prior fiscal year;
-- reported record quarterly net earnings of $7.5 million, a 34%
... |
| | | 11/26/07 | Meridian Bioscience Receives FDA Clearance for Two New Rapid Tests for the Detection of Influenza and Respiratory Syncytial Virus| CINCINNATI--(BUSINESS WIRE)--Nov. 26, 2007--Meridian Bioscience,
Inc. (NASDAQ:VIVO) today announced that it has received clearance from
the U.S. Food and Drug Administration (FDA) to market two new upper
respiratory tests: TRU FLU(R) and TRU RSV(R). These tests are based
upon a new rapid test technology that features improved safety and
space savings. TRU FLU(R) detects both influenza A and influenza B
while TRU RSV(R) detects for respiratory syncytial virus. These
companion tests are... |
| | | 11/14/07 | Meridian Bioscience Reports Record Fiscal 2007 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2007--Meridian Bioscience,
Inc.
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
-- reported record fourth quarter and full-year fiscal 2007 net
sales of $32.4 million and $123.0 million, respectively,
increases of 13% over the same periods of the prior fiscal
year;
-- reported record fourth quarter and full-year fiscal 2007
operating income of $8.6 mi... |
| | | 09/20/07 | Meridian Bioscience to Present at the UBS Global Life Science Conference| CINCINNATI--(BUSINESS WIRE)--Sept. 20, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company
has been invited to present at the UBS Global Life Science Conference
at the Grand Hyatt New York in New York City. Bill Motto, Chairman and
CEO and Jack Kraeutler, President and COO, are scheduled to present on
Wednesday, September, 26, 2007 at 2:00 p.m. ET. A question and answer
session will follow and some of the information provided during the
ses... |
| | | 09/19/07 | Meridian Bioscience to Present at the Sidoti & Company, LLC Sixth Annual West Coast Emerging Growth International Investor Forum| CINCINNATI--(BUSINESS WIRE)--Sept. 19, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company
has been invited to present at the Sidoti & Company, LLC Sixth Annual
West Coast Emerging Growth International Investor Forum at the
Ritz-Carlton Hotel in San Francisco. Bill Motto, Chairman and CEO and
Jack Kraeutler, President and COO, are scheduled to present on Monday,
September, 24, 2007 at 9:40 a.m. PDT. A question and answer session
will follow... |
| | | 08/28/07 | Meridian Bioscience, Inc. Announces the Commencement of Phase I/II Clinical Trials of Parvovirus B19 Vaccine| CINCINNATI--(BUSINESS WIRE)--Aug. 28, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced the commencement
of a Phase I/II Clinical Trial for a Parvovirus B19 Vaccine
manufactured by its wholly owned subsidiary, Meridian Life Science,
located in Memphis, Tennessee. The Investigational New Drug (IND)
Application for the Parvovirus B19 Vaccine was a collaborative effort
between Meridian Life Science and two branches of the National
Institutes of Health (NIH),... |
| | | 08/14/07 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2008 and Reaffirms Fiscal 2007 Guidance| CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today provided the financial
community with guidance regarding the Company's fiscal 2008 sales and
earnings estimates. Based on the Company's business planning and
budgeting activities for the fiscal year ending September 30, 2008,
management expects net sales to be in the range of $140 to $142
million and per share diluted earnings to be between $0.72 and $0.75.
The per share estimat... |
| | | 08/07/07 | Meridian Bioscience Awarded NIH Contract for Production of Experimental Vaccines| CINCINNATI--(BUSINESS WIRE)--Aug. 7, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly
owned subsidiary, Meridian Life Science, Inc. (MLS) was awarded a five
year contract (base year plus 4 option years) having a value of up to
$12.2 million by the National Institutes of Allergy and Infectious
Diseases (NIAID) of the National Institutes of Health (NIH). Meridian
will manufacture up to 10 clinical experimental vaccines per year at
its bioph... |
| | | 07/19/07 | Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Higher Fiscal 2007 Guidance, and Comments on Fiscal 2008 Outlook| CINCINNATI--(BUSINESS WIRE)--July 19, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
-- reported record third quarter and nine-month sales of
$29,763,000 and $90,577,000, respectively, an increase of 12%
and 14% over the same periods of the prior fiscal year;
-- reported record third quarter and nine-month operating income
of $9,473,000 and $26,350,000, respectively, an increase of
37% and 31% over the same period... |
| | | 06/05/07 | Meridian Bioscience Increases Earnings Per Share and Net Sales Guidance for Fiscal 2007| CINCINNATI--(BUSINESS WIRE)--June 5, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous
guidance for fiscal 2007 earnings from a range of $0.55 to $0.58 per
share (as adjusted for the May 11, 2007 three-for-two stock split) to
a new range of $0.57 to $0.60 per share. The per share estimates
assume an increase in average shares outstanding from approximately
40.2 million at fiscal 2006 year end to 40.5 million at fiscal 2007
year end. Net sales... |
| | | 05/03/07 | Meridian Bioscience to Present at the Robert W. Baird 2007 Growth Stock Conference| CINCINNATI, May 03, 2007 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the
Company has been invited to present at the Robert W. Baird 2007 Growth
Stock Conference on Thursday, May 10, 2007 at 12:35 p.m. CDT at the
Four Seasons Hotel in Chicago. Bill Motto, Chairman and Chief
Executive Officer and Jack Kraeutler, President and Chief Operating
Officer, are scheduled to present. A question and answer session will
follow the Company's presentation. The informa... |
| | | 04/19/07 | Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Splits Stock 3 for 2, and Increases Dividend| General Highlights
CINCINNATI--(BUSINESS WIRE)--April 19, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported record second quarter and six months net sales of
$32,094,000 and $60,814,000, respectively, an increase of 14%
over the same periods of the prior fiscal year;
reported record second quarter and six months net earnings of
$5,881,000 and $11,445,000, respectively, an increase of 25%
and 32% over ... |
| | | 02/20/07 | Meridian Bioscience Receives FDA Clearance for New E. coli Test| Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard STAT!® EHEC, a revolutionary new test for the diagnosis of E. coli infection. The new product detects all Shiga-toxin producing E. coli and is the first rapid (20 minute) E. coli diagnostic that differentiates between Toxin 1 & Toxin 2.
With the recent national E. coli outbreaks (spinach in September 2006 and lettuce i... |
| | | 01/30/07 | Meridian Bioscience Announces Final Redemption of its 5% Convertible Subordinated Debentures| CINCINNATI--(BUSINESS WIRE)--Jan. 30, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has
called for redemption on March 1, 2007, all of its outstanding 5%
Convertible Subordinated Debentures due September 1, 2013, at a 1%
call premium plus accrued interest. At January 29, 2007, there were
approximately $1.5 million of principal amount of such debentures
outstanding.
On or prior to the close of business on February 27, 2007, holders
of the ... |
| | | 01/18/07 | Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2007 Guidance| GENERAL HIGHLIGHTS
CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
-- reported record first quarter net sales of $28,720,000, a 15%
increase over the same period of the prior fiscal year;
-- reported record quarterly net earnings of $5,564,000, a 40%
increase over the same period of the prior fiscal year;
-- reported record first quarter diluted per share earnings of
$0.21,... |
| | | 01/04/07 | Meridian Bioscience Completes Production of Clinical Respiratory Syncytial Virus (RSV) for Human Clinical Trials| CINCINNATI--(BUSINESS WIRE)--Jan. 4, 2007--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly
owned subsidiary, Meridian Life Science, Inc. (MLS), formerly Viral
Antigens, Inc., completed manufacturing of a clinical infectious
inoculum of respiratory syncytial virus (RSV) in its biopharmaceutical
facility located in Memphis, TN. The RSV clinical material will be
used by a contract biopharmaceutical client to conduct human challenge
studies in ord... |
| | | 11/15/06 | Meridian Bioscience Reports Record Fiscal 2006 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 15, 2006--Meridian Bioscience,
Inc. (NASDAQ:VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc. (NASDAQ:VIVO) today:
reported record fiscal 2006 net sales of $108.4 million and
record diluted earnings per share of $0.68, respective
increases of 17% and 31% over the prior fiscal year;
reported record fourth quarter fiscal 2006 net sales of $28.7
million and diluted earnings per share of $0.18, respecti... |
| | | 10/25/06 | Meridian Licenses Molecular Test Technology from Eiken Chemical Co., Ltd.| CINCINNATI--(BUSINESS WIRE)--Oct. 25, 2006--Meridian Bioscience,
Inc., (NASDAQ:VIVO) announced that it has completed a license
agreement with Eiken Chemical Co., Ltd., Japan, for its "LAMP"
(Loop-mediated Isothermal Amplification) technology. The LAMP
technology is a cutting-edge nucleic acid amplification method that is
simple to perform, rapid, highly specific and performed at a single
temperature. Unlike other amplification methods, no specialized
equipment is necessary to perform ... |
| | | 10/17/06 | Meridian Bioscience Again Recognized by Forbes as One of the 200 Best Small Companies| CINCINNATI--(BUSINESS WIRE)--Oct. 17, 2006--Meridian Bioscience,
Inc. (NASDAQ:VIVO) today announced that it has been recognized by
Forbes as one of "The 200 Best Small Companies" for the fourth year in
a row. The 200 Best Small Companies list is selected following a
comprehensive evaluation of financial results plus additional
operating factors of candidate companies having sales between $5
million and $750 million. Additional qualification criteria included a
consistent pattern of po... |
| | | 09/21/06 | Meridian Bioscience to Present at UBS Global Life Science Conference| CINCINNATI--(BUSINESS WIRE)--Sept. 21, 2006--Meridian Bioscience,
Inc. (NASDAQ:VIVO) today announced that the Company has been invited
to present at the UBS Global Life Sciences Conference, Tuesday,
September 26, 2006 at 1:30 p.m. ET at the Grand Hyatt New York in New
York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President
and COO, are scheduled to present. A question and answer session will
follow and some of the information provided during the session may not
have been... |
| | | 08/14/06 | Meridian Partners with Merck KGaA/Germany to Develop New Products| CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2006--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has
entered into a partnership agreement with the Performance & Life
Science Chemicals Division of Merck KGaA, Darmstadt, Germany and its
American company EMD. This strategic partnership is focused on the
development of new assays for the clinical market, which Meridian will
sell through its established, best-in-class sales force and
distribution partners. This... |
| | | 08/09/06 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2007 and Reaffirms Fiscal 2006 Guidance| CINCINNATI--(BUSINESS WIRE)--Aug. 9, 2006--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today provided the financial community with
guidance regarding the Company's fiscal 2007 sales and earnings
estimates. Based on the Company's business planning and budgeting
activities for the fiscal year ending September 30, 2007, management
expects net sales to be in the range of $118 to $123 million and per
share diluted earnings to be between $0.83 and $0.87. The per share
estimates assume an incre... |
| | | 07/20/06 | Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Higher Fiscal 2006 Guidance, and Comments on Fiscal 2007 Outlook| CINCINNATI--(BUSINESS WIRE)--July 20, 2006--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported record third quarter and nine-month sales of
$26,583,000 and $79,763,000, respectively, an increase of 5%
and 17% over the same periods of the prior fiscal year;
reported record third quarter and nine-month operating income
of $6,893,000 and $20,040,000, respectively, an increase of
21% and 39% over the same periods of the prior ... |
| | | 07/06/06 | Meridian Bioscience Announces Its Inclusion in the New NASDAQ Global Select Market - The Market With the Highest Initial Listing Standards in the World -| CINCINNATI, Jul 06, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio
(NASDAQ:VIVO) today announced that it is included in the new NASDAQ
Global Select Market. The NASDAQ Global Select Market has the highest
initial listing standards of any exchange in the world based on
financial and liquidity requirements. Prior to the change, the company
had been listed on the NASDAQ National Market.
Beginning July 3, NASDAQ-listed companies will be classified under
three listing ti... |
| | | 06/26/06 | FORTUNE Small Business Ranks America's Fastest-Growing Small Companies| CINCINNATI--(BUSINESS WIRE)--June 26, 2006--FORTUNE Small Business
announced today that Meridian Bioscience, Inc. (NASDAQ:VIVO) has been
ranked 66 on the sixth annual FSB 100 list of the fastest growing
small companies in America. The list, which is comprised of public
companies, appears in the July/August issue of FORTUNE Small Business
and is available at FSB.com.
John A. Kraeutler, President and Chief Operating Officer, stated,
"We would like to thank FORTUNE Small Business for... |
| | | 06/15/06 | Meridian Bioscience to Present at the InvesTristate Regional Public Company Investment Conference| CINCINNATI--(BUSINESS WIRE)--June 15, 2006--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company
has been invited to present at the InvesTristate Regional Public
Company Investment Conference on Tuesday, June 20, 2006 at 10:55 a.m.
ET at the Hyatt Regency, Cincinnati, Ohio. Jack Kraeutler, President
and Chief Operating Officer and Melissa Lueke, Vice President and
Chief Financial Officer, are scheduled to present. A question and
answer session wil... |
| | | 06/12/06 | Meridian Bioscience Receives FDA CLIA Waiver Status for Stomach Ulcer Test| CINCINNATI--(BUSINESS WIRE)--June 12, 2006--Meridian Bioscience,
Inc. (NASDAQ:VIVO) today announced that it has received CLIA waiver
status from the U.S. Food and Drug Administration (FDA) for its
ImmunoCard STAT!(R) HpSA test, a rapid single-use test for the
diagnosis of Helicobacter pylori (H. pylori) infection. The vast
majority of peptic ulcer disease is caused by infection with H. pylori
bacteria and, in recent years, effective therapies have become
available for eradicating this... |
| | | 05/05/06 | Meridian Bioscience to Present at the Robert W. Baird 2006 Growth Stock Conference| CINCINNATI, May 05, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio
(NASDAQ:VIVO) today announced that the Company has been invited to
present at the Robert W. Baird 2006 Growth Stock Conference on
Tuesday, May 9, 2006 at 12:40 p.m. CDT at the Four Seasons Hotel in
Chicago. Bill Motto, Chairman and Chief Executive Officer and Jack
Kraeutler, President and Chief Operating Officer, are scheduled to
present. A question and answer session will follow and some of the
inform... |
| | | 05/03/06 | Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)| CINCINNATI--(BUSINESS WIRE)--May 3, 2006--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been
added to Mergent's Dividend Achievers Index(TM) for 2006. This index
is made up of just 3% of U.S. publicly traded companies with the most
consistent records of annual dividend increases.
Quoting from Mergent's correspondence, "This designation means
that you (Meridian Bioscience, Inc.) are part of an elite class of
companies that have successfully d... |
| | | 04/20/06 | Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Increases Fiscal 2006 Guidance, and Declares Regular Cash Dividend General Highlights| CINCINNATI, Ohio--(BUSINESS WIRE)--April 20, 2006--Meridian
Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported record second quarter and six months net sales of
$28,272,000 and $53,180,000, respectively, an increase of 19%
and 25% over the same periods of the prior fiscal year;
reported record second quarter and six months net earnings of
$4,723,000 and $8,685,000, respectively, an increase of 48%
and 64% over the same periods of t... |
| | | 04/12/06 | Meridian Bioscience Helicobacter Pylori Patent Validated by Settlement Agreement With Astra S.r.l.| CINCINNATI--(BUSINESS WIRE)--April 12, 2006--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has
executed a settlement agreement with Astra S.r.l. regarding Meridian's
patented technology for detecting H. pylori, the primary cause of
peptic ulcers. In the agreement, Astra acknowledges the existence,
validity and scope of Meridian's patent, EPO 0806667. Astra further
agrees to: 1) cease all promotion and distribution of its infringing
products, and; 2)... |
| | | 03/16/06 | Meridian Bioscience Receives FDA Clearance for New Stomach Ulcer Test| CINCINNATI--(BUSINESS WIRE)--March 16, 2006--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that it has received clearance
from the U.S. Food and Drug Administration (FDA) to market Premier
Platinum HpSA(R) Plus, an improved new test for the diagnosis of
Helicobacter pylori (H. pylori) infection. The vast majority of peptic
ulcer disease is caused by infection with H. pylori bacteria and, in
recent years, effective therapies have become available for
eradicating this disease... |
| | | 02/24/06 | Meridian Bioscience Named Founding Member to New NASDAQ Dividend Achievers Index| CINCINNATI--(BUSINESS WIRE)--Feb. 24, 2006--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that it has been included in the
new NASDAQ Dividend Achievers Index as a founding member. Quoting, in
part, from the February 22, 2006 press release of the NASDAQ Stock
Market, Inc.
The NASDAQ Dividend Achievers Index is designed to track the
performance of U.S. companies that are listed on NASDAQ and meet
Dividend Achievers requirements of increased annual regular
... |
| | | 01/19/06 | Meridian Bioscience Reports Record First Quarter Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2006 Guidance| CINCINNATI, Jan 19, 2006 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio today:
reported record first quarter net sales of $24,908,000, a 32%
increase over the same period of the prior fiscal year;
reported record first quarter net earnings of $3,962,000, an
88% increase over the same period of the prior fiscal year;
reported record first quarter diluted per share earnings of
... |
| | | 11/10/05 | Meridian Bioscience Reports Record Fiscal 2005 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance| CINCINNATI, Nov 10, 2005 (BUSINESS WIRE) -- GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported record fiscal 2005 net sales of $93 million and
record diluted earnings per share of $0.52, respective
increases of 17% and 30% over the prior fiscal year;
reported fourth quarter fiscal 2005 net sales of $25 million
and diluted earnings per share of $0.15, respective increases
of 12% and 15% over the same period ... |
| | | 10/31/05 | Meridian Bioscience Again Recognized by Forbes as One of The 200 Best Small Companies| CINCINNATI--(BUSINESS WIRE)--Oct. 31, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been
recognized by Forbes as one of "The 200 Best Small Companies" for the
third year in a row. The 200 Best Small Companies list is selected
following a comprehensive evaluation of financial results plus
additional operating factors of candidate companies having sales
between $5 million and $750 million. Additional qualification criteria
included a consist... |
| | | 10/18/05 | Meridian Bioscience H. Pylori Patent Upheld by European Patent Office| CINCINNATI--(BUSINESS WIRE)--Oct. 18, 2005--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that its patent entitled
"Immunoassay for Helicobacter pylori in Fecal Specimens" has been
confirmed as valid by the European Patent Office. The validity of the
Patent had been challenged in four Oppositions filed by a total of
seven parties. The objections raised were that the Patent added
subject matter to the Application as originally filed, lacked novelty,
lacked inventive steps an... |
| | | 09/23/05 | Meridian Bioscience to Present at UBS Global Life Science Conference| CINCINNATI--(BUSINESS WIRE)--Sept. 23, 2005--Meridian Bioscience,
Inc. (NASDAQ:VIVO) today announced that the Company has been invited
to present at the UBS Global Life Sciences Conference, Tuesday,
September 27, 2005 at 12:00 p.m. ET at the Grand Hyatt New York in New
York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President
and COO, are scheduled to present. A question and answer session will
follow and some of the information provided during the session may not
have bee... |
| | | 09/16/05 | Meridian Bioscience Announces Pricing of $58 Million Common Stock Offering| CINCINNATI, Sep 16, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio
(NASDAQ:VIVO) today announced that it has priced a public offering of
3,300,000 shares of common stock at $17.50 per share. Of the total
number of shares, 1,800,000 shares are being offered by the Company,
and 1,500,000 shares are being offered by The William J. Motto
Irrevocable Family Trust. Mr. Motto is the Company's Chairman and
Chief Executive Officer. The shares are being offered pursuant to a
sh... |
| | | 08/15/05 | Meridian Bioscience Announces 3-for-2 Stock Split and Provides Sales and Earnings Guidance for Fiscal 2006| CINCINNATI--(BUSINESS WIRE)--Aug. 15, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its Board of
Directors has declared a three-for-two stock split of the Company's
common shares. The record date is August 29, 2005 with the payment
date set for September 2, 2005. Cash will be paid in lieu of
fractional shares.
Management also today provided the financial community with
guidance regarding the Company's fiscal 2006 sales and earnings
estimates. ... |
| | | 07/21/05 | Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, and Reaffirms Higher Fiscal 2005 Guidance| CINCINNATI--(BUSINESS WIRE)--July 21, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported record third quarter sales of $25,421,000, a 39%
increase over the same period of the prior fiscal year and an
all-time record for any quarter in the Company's history;
reported record third quarter operating income of $5,708,000,
an increase of 70% over the same period of the prior fiscal
year and an all-time record for any qu... |
| | | 07/11/05 | Meridian Bioscience Increases Earnings Per Share and Net Sales Guidance for Fiscal 2005| CINCINNATI--(BUSINESS WIRE)--July 11, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous
guidance for fiscal 2005 earnings from a range of $0.66 to $0.70 per
share to a new range of $0.73 to $0.76 per share. The per share
estimates assume an increase in average shares outstanding from
approximately 15.3 million at fiscal 2004 year end to 16.1 million at
fiscal 2005 year end. Due to stronger than expected third quarter
shipments, net sales guidance... |
| | | 07/07/05 | Meridian Bioscience Awarded Exclusive, Global License for Parvovirus B19 Vaccine from the National Institutes of Health| CINCINNATI, Jul 07, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced
that its wholly-owned subsidiary, Viral Antigens, Inc. (VAI), Memphis,
TN, was awarded the exclusive global license for the recombinant
Parvovirus B19 Vaccine technology from the National Institutes of
Health (NIH). The license provides VAI with the exclusive and global
rights to utilize the NIH's patented technology to develop,
manufacture, and market the Parvovirus B19 vaccine.
Previo... |
| | | 07/06/05 | Meridian Bioscience Added to Mergent's Dividend Achievers Index(TM)| CINCINNATI, Jul 06, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio
(NASDAQ:VIVO) today announced that it has been added to Mergent's
Dividend Achievers Index(TM) for 2005. This index is made up of 314
stocks composed of U.S. companies with the most consistent records of
annual dividend increases.
Quoting from Mergent's press release, "Dividend Achievers
represent the elite of the U.S. stock market. These are generally well
known companies that as a group have been... |
| | | 06/22/05 | New Meridian Bioscience Patent Improves Rubella Testing Accuracy| CINCINNATI--(BUSINESS WIRE)--June 22, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that Viral
Antigens, Inc. (VAI), a wholly owned life science subsidiary, received
a patent entitled "Specificity in the Detection of Anti-Rubella IgM
Antibodies" from the U.S. Patent and Trademark Office. This patent
encompasses improved methods for detection of anti-rubella IgM
antibodies in commercial diagnostic products, utilized to test blood
samples for the presence o... |
| | | 06/20/05 | Fortune Small Business Ranks Meridian Bioscience Among America's Fastest-Growing Small Companies| CINCINNATI--(BUSINESS WIRE)--June 20, 2005--(NASDAQ:VIVO) -
FORTUNE Small Business announced today that Meridian Bioscience, Inc.,
has been ranked 80 on the fifth annual FSB 100 list of the 100 fastest
growing small companies in America. The list, which is comprised of
public companies, appears in the July/August issue of FORTUNE Small
Business, available on newsstands July 4 and at www.fsb.com.
John A. Kraeutler, President and Chief Operating Officer, stated,
"This recognition by F... |
| | | 06/14/05 | Meridian Bioscience Announces Final Redemption of Its 7% Convertible Subordinated Debentures| CINCINNATI, Jun 14, 2005 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio
(NASDAQ:VIVO) today announced that it has called for redemption on
July 8, 2005, all of its outstanding 7% Convertible Subordinated
Debentures due September 1, 2006, at par plus accrued interest. At
June 10, 2005, there were approximately $1.8 million of principal
amount of such debentures outstanding.
On or prior to the close of business on July 7, 2005, holders of
the 7% Convertible Debentures be... |
| | | 06/01/05 | Meridian Bioscience Recognized as One of the 100 Best Small Companies of 2005 by Business Week Magazine| CINCINNATI--(BUSINESS WIRE)--June 1, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has been
recognized by Business Week magazine as one of "The 100 Best Small
Companies." The 100 Best Small Companies list is selected following a
comprehensive evaluation of financial results plus additional
operating factors of candidate companies having sales between $50
million and $1.5 billion. Additional qualification criteria included
rankings based upon sales... |
| | | 05/10/05 | Meridian Bioscience to Present at the Robert W. Baird 2005 Growth Stock Conference| CINCINNATI--(BUSINESS WIRE)--May 10, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company
has been invited to present at the Robert W. Baird 2005 Growth Stock
Conference on Wednesday, May 11, 2005 at 2:05 p.m. CDT at the Four
Seasons Hotel in Chicago. Bill Motto, Chairman and Chief Executive
Officer and Jack Kraeutler, President and Chief Operating Officer, are
scheduled to present. A question and answer session will follow and
some of the infor... |
| | | 05/09/05 | Meridian Bioscience Announces Third Partial Redemption of Its 7% Convertible Subordinated Debentures| CINCINNATI--(BUSINESS WIRE)--May 9, 2005--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that it has called for redemption
on June 3, 2005, $2.5 million in principal amount of its outstanding
7% Convertible Subordinated Debentures due September 1, 2006, at par
plus accrued interest. The called 7% Convertible Debentures will be
selected in accordance with the applicable procedures of the Trustee,
U.S. Bank, National Association, for partial redemption. Holders of 7%
Convertible D... |
| | | 04/21/05 | Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2005 Guidance| CINCINNATI--(BUSINESS WIRE)--April 21, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported all-time record quarterly sales of $23,686,000, a 13%
increase over the same period of the prior fiscal year and an
all-time record for any quarter in the Company's history;
reported all-time record quarterly operating income of
$5,198,000, an increase of 31% over the same period of the
prior fiscal year and an all-time recor... |
| | | 04/13/05 | Meridian Bioscience Announces Preliminary Operating Results for the Second Quarter, Reaffirms Guidance, and Comments on Recommended Destruction of Influenza A Samples| CINCINNATI--(BUSINESS WIRE)--April 13, 2005--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that, based on preliminary
results, it expects to report net sales of approximately $23.5 million
and diluted earnings per share of between $0.19 and $0.20 for the
quarter ended March 31, 2005. For the same period of the previous
fiscal year, sales and diluted earnings per share were $20.94 million
and $0.15, respectively. The Company will report its final results for
the fiscal second qu... |
| | | 03/16/05 | Meridian Bioscience Expands Presence in Veterinary Market and Announces Agreement with Synbiotics Corporation| CINCINNATI--(BUSINESS WIRE)--March 16, 2005--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that its wholly owned subsidiary,
Viral Antigens, Inc. (VAI), has entered into a Distribution Agreement
with Synbiotics Corporation for the distribution of VAI's veterinary
products through Synbiotics' global sales, marketing, and distribution
channels. Synbiotics develops, manufactures, and markets veterinary
diagnostic products for the animal health market and is seeking to
broaden its ... |
| | | 03/01/05 | Meridian Bioscience to Present at Friedman, Billings, Ramsey & Co. 2005 Washington Conference| CINCINNATI, Mar 1, 2005 (BUSINESS WIRE) -- Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company
has been invited to present at the Friedman, Billings, Ramsey & Co.
2005 Washington Conference on Thursday, March 3, 2005 at 2:20 p.m. EST
at the Mandarin Oriental Washington in Washington, D.C. The Conference
will feature presentations from companies representing Homeland
Security, Defense and Government IT. Jack Kraeutler, President and
Chief Operating Of... |
| | | 02/09/05 | Meridian Bioscience Targets Biodefense Market by Providing Contract Services for BEI Resources| CINCINNATI--(BUSINESS WIRE)--Feb. 9, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its
wholly-owned subsidiary, Viral Antigens, Inc. (VAI) has entered the
emerging biodefense market by providing contract services for
Biodefense and Emerging Infections (BEI) Resources. BEI Resources was
established by the National Institute of Allergy and Infectious
Diseases (NIAID) of the National Institutes of Health (NIH) to
acquire, authenticate, and produce reage... |
| | | 02/01/05 | Meridian Bioscience Completes Acquisition of O.E.M. Concepts and Comments on New Growth Opportunities| CINCINNATI--(BUSINESS WIRE)--Feb. 1, 2005--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that it has completed the purchase
of O.E.M. Concepts, Inc., highlights include:
purchase price of $6.0 million in cash and a performance
based earnout opportunity of $2.3 million over a four-year
period, as previously reported;
earnings accretion of between $0.01 and $0.02 for the
balance of fiscal 2005 and $0.04 to $0.06 for fiscal 2006
... |
| | | 01/20/05 | Meridian Bioscience Reports Record First Quarter Operating Results, Executes Agreement To Buy O.E.M. Concepts, Declares Higher Dividend, and Reaffirms Fiscal 2005 Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 20, 2005--Meridian Bioscience,
Inc., (NASDAQ:VIVO)
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported record first quarter net sales of $18,842,000, a 4%
increase over the same period of the prior fiscal year;
reported record first quarter net earnings of $2,110,000, an
18% increase over the same period of the prior fiscal year;
reported record first quarter dilu... |
| | | 01/18/05 | Meridian Bioscience Reports Completion of 7% Convertible Debentures Redemption| CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2005--Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its call for
the redemption of $4.0 million in principal amount of its outstanding
7% Convertible Subordinated Debentures Due September 1, 2006, was
successfully completed on January 14, 2005, as planned. The result of
the redemption call was that $3.4 million was converted into 211,000
shares of the Company's underlying common stock and $603,000 was
redeemed at par v... |
| | | 12/20/04 | Meridian Bioscience Announces Second Partial Redemption of Its 7% Convertible Subordinated Debentures| CINCINNATI, Dec 20, 2004 (BUSINESS WIRE) -- Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that it has called for redemption
on January 14, 2005, four million dollars ($4 million) in principal
amount of its outstanding 7% Convertible Subordinated Debentures due
September 1, 2006, at par plus accrued interest. The called 7%
Convertible Debentures will be selected in accordance with the
applicable procedures of the Trustee, U.S. Bank, National Association,
for partial redemption. ... |
| | | 11/17/04 | Meridian Bioscience Reports Record Fiscal 2004 Operating Results and Increases Regular Cash Dividend Rate for Fiscal 2005| CINCINNATI--(BUSINESS WIRE)--Nov. 17, 2004--Meridian Bioscience,
Inc., (NASDAQ:VIVO)
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today:
reported record fiscal 2004 net sales of $79.6 million and
diluted earnings per share of $0.60, respective increases of
21% and 28% over the prior fiscal year;
reported record fourth quarter fiscal 2004 net sales of $22.2
million and diluted earnings per share of $0.19... |
| | | 11/15/04 | Meridian Bioscience Increases Fiscal 2005 Earnings Per Share Guidance| CINCINNATI, Nov 15, 2004 (BUSINESS WIRE) -- Meridian Bioscience,
Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous
guidance for fiscal 2005 earnings from a range of $0.62 to $0.66 per
share to a new range of $0.66 to $0.70 per share. The per share
estimates assume an increase in average shares outstanding from
approximately 15.3 million at fiscal 2004 year end to 15.6 million at
fiscal 2005 year end. Management continues to believe net sales will
be in the range of $84 to ... |
| | | 11/10/04 | Meridian Signs Agreement in Principle to Acquire Leading Manufacturer and Distributor of Biological Components| CINCINNATI--(BUSINESS WIRE)--Nov. 10, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced it has executed a letter of intent
to acquire all the outstanding capital stock of O.E.M. Concepts, Inc.,
a leading producer and distributor of biological components
headquartered in Toms River, New Jersey. The purchase price includes
cash and future performance-based earn out opportunities, the amounts
of which were not disclosed. O.E.M. Concepts' management team will
remain in place and ... |
| | | 10/21/04 | Meridian Bioscience Again Recognized by Forbes as One of the 200 Best Small Companies| CINCINNATI--(BUSINESS WIRE)--Oct. 21, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has been recognized by
Forbes as one of "The 200 Best Small Companies" for the second year in
a row. The 200 Best Small Companies list is selected following a
comprehensive evaluation of financial results plus additional
operating factors of candidate companies having sales between $5
million and $750 million. Additional qualification criteria included a
consistent pattern of posit... |
| | | 10/05/04 | Meridian Bioscience Announces Award Of SBIR Grant and Submission of Proposal for Biodefense Program| CINCINNATI--(BUSINESS WIRE)--Oct. 5, 2004--Meridian Bioscience,
Inc. (Nasdaq:VIVO) announced today it has been awarded a Phase I Small
Business Innovation Research (SBIR) Grant from the National Institutes
of Health (NIH). This Phase I Grant will help fund research to develop
highly specific recombinant antibodies to Clostridium difficile toxins
A&B and then use these unique antibodies to develop rapid, inexpensive
and sensitive diagnostics. Meridian will continue to pursue additional
... |
| | | 09/23/04 | Meridian Bioscience to Present at UBS Global Life Science Conference| CINCINNATI--(BUSINESS WIRE)--Sept. 23, 2004--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that the Company has been invited
to present at the UBS Global Life Science Conference, Wednesday,
September 29, 2004 at 4:30 p.m. EDT at the Grand Hyatt New York in New
York City. Jack Kraeutler, President and Chief Operating Officer, has
been scheduled to present. A question and answer session will follow
and some of the information provided during the session may not have
been previousl... |
| | | 08/26/04 | Meridian Bioscience Announces FDA Clearance of New Rapid Test for Severe Colitis| CINCINNATI--(BUSINESS WIRE)--Aug. 26, 2004--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has
received clearance from the U.S. Food and Drug Administration (FDA) to
market ImmunoCard Toxins A&B, a rapid new test for the diagnosis of a
major cause of antibiotic-associated colitis. This test detects the
most important toxins produced by strains of the Clostridium difficile
bacterium (C. difficile). C. difficile is recognized as the major
cause of colitis ... |
| | | 08/03/04 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2005| CINCINNATI--(BUSINESS WIRE)--Aug. 3, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today provided the financial community with
guidance regarding the Company's fiscal 2005 sales and earnings
estimates. Based on the Company's business planning and budgeting
activities, for the fiscal year ending September 30, 2005, management
expects net sales to be in the range of $84 to $88 million and per
share diluted earnings to be between $0.62 and $0.66. The per share
estimates assume an increase i... |
| | | 08/02/04 | Meridian Bioscience to Present at Baird's 2004 Small Cap Conference| CINCINNATI--(BUSINESS WIRE)--Aug. 2, 2004--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief
Executive Officer; Jack Kraeutler, President and Chief Operating
Officer; and Rick Eberly, Executive Vice President and General
Manager, Meridian Life Science, have been invited to present at
Baird's 2004 Small Cap Conference Wednesday, August 4, 2004 at 2:20
p.m. EDT at the Pierre Hotel in New York City. A question and answer
session will follow and some ... |
| | | 07/22/04 | Meridian Bioscience Reports Record Third Quarter Sales, Higher Earnings, Declares Regular Dividend, and Reaffirms Fiscal 2004 Guidance| CINCINNATI--(BUSINESS WIRE)--July 22, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today:
reported record third quarter sales of $18,256,000, a 16%
increase over last year's third quarter;
reported diluted earnings per share of $0.14, a 17% increase
over the same period last year;
declared a regular cash dividend of $0.10 per share, 11%
higher than the quarterly rate of fiscal 2003; and
reaffirmed its recently increased guidance of sales be... |
| | | 06/29/04 | Meridian Bioscience Recognized as One of Ohio's Top Exporters in 2004| CINCINNATI--(BUSINESS WIRE)--June 29, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has been recognized by the
Governor of the State of Ohio, the Honorable Bob Taft, as one of
Ohio's top exporters in 2004.
Meridian was honored with a Governor's Excellence in Exporting
Award ("E" Award) in a ceremony on June 24, 2004. The Governor's "E"
Award recognizes Ohio companies that have increased sales through
exports, have increased Ohio-Based employment as a direct ... |
| | | 06/03/04 | Meridian Bioscience Enters Strategic Collaboration With Viral Therapeutics| CINCINNATI--(BUSINESS WIRE)--June 3, 2004--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its
wholly-owned subsidiary, Viral Antigens, Inc. (VAI), has entered into
a strategic collaboration with Viral Therapeutics, Inc. (VTI), Ithaca,
NY, to support the clinical and commercial development needs of
biopharmaceutical partners. Viral Therapeutics is an expert in the
development of recombinant proteins and in production optimization.
Viral Antigens' expertise i... |
| | | 05/26/04 | Meridian Bioscience Announces Licensing Agreement With Cincinnati Children's Research Foundation| CINCINNATI--(BUSINESS WIRE)--May 26, 2004--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that it has entered into a license
agreement with Cincinnati Children's Research Foundation for
technologies related to the detection of norovirus, the primary cause
of "stomach flu". This agreement, which is comprised of both exclusive
and co-exclusive provisions, encompasses products for the clinical
diagnosis of noroviruses and other products arising from the
technology.
Noroviruse... |
| | | 05/17/04 | Meridian Bioscience Announces European Launch of New Rapid Test for Severe Colitis| CINCINNATI--(BUSINESS WIRE)--May 17, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has begun to sell its
newest product, ImmunoCard Toxins A&B in the European market. This
important new test detects toxins produced by strains of the
Clostridium difficile bacterium (C. difficile). C. difficile is
recognized as the major causative agent of colitis (inflammation of
the colon) and diarrhea that may occur following antibiotic therapy.
In hospitals or nursing home facil... |
| | | 04/22/04 | Meridian Bioscience Reports Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Increases Fiscal 2004 Guidance| CINCINNATI--(BUSINESS WIRE)--April 22, 2004--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today:
reported all-time record quarterly sales of $20,940,000, a 24%
increase over the same period of the prior fiscal year and
all-time record for any quarter in the Company's history;
reported all-time record quarter operating income of
$3,981,000, an increase of 5% over the same period of the
prior fiscal year and an all-time record for ... |
| | | 03/18/04 | Meridian Bioscience Added to Mergent's Dividend Achievers Index| CINCINNATI--(BUSINESS WIRE)--March 18, 2004--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that it has been added to Mergent's
Dividend Achievers Index(TM) for 2004. This index is made up of 303
stocks composed of U.S. companies with the most consistent records of
annual dividend increases.
Quoting from Mergent's press release "Dividend Achievers(TM) are
publicly listed U.S. companies that have increased regular dividends
for the past 10 consecutive years or longer, and th... |
| | | 02/03/04 | Meridian Bioscience Granted International ISO Certification to Manufacture Medical Devices for Export| CINCINNATI--(BUSINESS WIRE)--Feb. 3, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has completed all
activities required for ISO 13485 registration and final
certification.
ISO 13485 is a quality systems approach to managing the processes
for manufacturing medical devices to ensure that they conform to
customer expectations and governmental standards. More than 75
countries recognize ISO 13485 as the standard of practice for medical
device manufacturing. In... |
| | | 01/30/04 | Meridian Bioscience Reports Completion of Exchange Offer| CINCINNATI--(BUSINESS WIRE)--Jan. 30, 2004--Meridian Bioscience,
Inc., (NASDAQ:VIVO) today announced that its offer to exchange 5%
Convertible Subordinated Debentures due 2013 for its outstanding 7%
Convertible Subordinated Debentures due 2006, expired at 12:00
midnight EST on Wednesday, January 28, 2004.
LaSalle Bank National Association, the exchange agent for the
offer, has advised the Company that approximately $4 million in
principal amount of the outstanding debentures was ten... |
| | | 01/27/04 | Meridian Bioscience Awarded New Rubella Patent| CINCINNATI, Jan 27, 2004 (BUSINESS WIRE) -- Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Viral
Antigens, Inc. (VAI), a wholly owned life science subsidiary, received
a patent entitled "Improved Specificity in the Detection of
Anti-Rubella IgM Antibodies" from the U.S. Patent and Trademark
Office. This patent encompasses improved methods for detection of
anti-rubella IgM antibodies in commercial diagnostic products,
utilized to test blood samples for the p... |
| | | 01/22/04 | Meridian Bioscience Reports Record Sales and Record First Quarter Operating Income, Declares First Quarter Higher Regular Cash Dividend, and Reaffirms Fiscal 2004 Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today:
reported record quarterly net sales of $18,166,000, a 13%
increase over the same period of the prior fiscal year and an
all time record for any quarter in the Company's history;
reported diluted net earnings of $1,795,000 or $0.12 per
diluted share, a 26% increase over the same period of the
prior fiscal year;
reported record first quarter oper... |
| | | 01/13/04 | Meridian Bioscience to Begin Redeeming 7% Convertible Subordinated Debentures| CINCINNATI--(BUSINESS WIRE)--Jan. 13, 2004--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that it will begin a program to
redeem at par its outstanding issue of 7% Convertible Subordinated
Debentures due 2006. The first call for redemption, in the amount of
$4 million, will take place soon after January 28, 2004, the date when
debentureholders lose their right to exchange their current debentures
for new debentures. It is anticipated that the Company will make
additional redempt... |
| | | 01/12/04 | Meridian Bioscience Hires Vice President of Sales and Marketing| CINCINNATI--(BUSINESS WIRE)--Jan. 12, 2004--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that Gregory S. Ballish has joined
Meridian Bioscience, Inc. as Vice President Sales and Marketing.
Ballish joins Meridian as a pharmaceutical and diagnostics industry
veteran, having spent the last five years in senior sales management
and strategic customer marketing roles with Janssen Pharmaceutica
(Johnson & Johnson subsidiary). Mr. Ballish has also held positions of
national sales and... |
| | | 12/23/03 | Meridian Bioscience Extends Expiration Date of Exchange Offer| CINCINNATI--(BUSINESS WIRE)--Dec. 23, 2003--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that it is extending the expiration
date for its offer to exchange 5% Convertible Subordinated Debentures
due 2013 (New Debentures) in the principal amount of $16,000,000 for
an equal amount of outstanding 7% Convertible Subordinated Debentures
due 2006 (Existing Debentures), and related withdrawal rights, until
12:00 midnight EST on Wednesday, January 28, 2004, unless extended or
earlier t... |
| | | 12/12/03 | Meridian Bioscience Extends Expiration Date of Exchange Offer| CINCINNATI--(BUSINESS WIRE)--Dec. 12, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it is extending the
expiration date for its offer to exchange 5% Convertible Subordinated
Debentures due 2013 (New Debentures) in the principal amount of
$16,000,000 for an equal amount of outstanding 7% Convertible
Subordinated Debentures due 2006 (Existing Debentures), and related
withdrawal rights, until 12:00 midnight EST on Tuesday, December 30,
2003, unless extended or earlier t... |
| | | 12/11/03 | Meridian Bioscience Launches New Flu Test for Physician Offices| CINCINNATI--(BUSINESS WIRE)--Dec. 11, 2003--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that it has begun marketing a new
physician's office Influenza A&B Test. This rapid test is simple
enough to be performed in physicians' offices and small labs. The new
product expands Meridian's influenza and RSV testing lines that
continue to be in high demand and have been sold to hospital labs for
the past two years. This rapid physician's office flu test
differentiates between the A an... |
| | | 12/09/03 | Meridian Bioscience Announces New Rapid Test for Stomach Ulcers| CINCINNATI--(BUSINESS WIRE)--Dec. 9, 2003--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has
received clearance from the U.S. Food and Drug Administration (FDA) to
market ImmunoCard STAT!(R) HpSA, a rapid new test for the diagnosis of
Helicobacter pylori (H. pylori) infection. The vast majority of peptic
ulcer disease is caused by infection with H. pylori bacteria and, in
recent years, effective therapies have become available for
eradicating this patho... |
| | | 11/25/03 | Meridian Bioscience to Present at Friedman Billings Ramsey 10th Annual Investor Conference| CINCINNATI--(BUSINESS WIRE)--Nov. 25, 2003--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief
Executive Officer; Jack Kraeutler, President and Chief Operating
Officer; and Rick Eberly, Executive Vice President and General
Manager, Meridian Life Science, have been invited to present at the
Friedman Billings Ramsey 10th Annual Investor Conference on Tuesday,
December 2, 2003 at 9:30 a.m. ET at the Sheraton New York Hotel &
Towers in New York City. A... |
| | | 11/18/03 | Meridian Bioscience Reports Fiscal 2003 Year End and Fourth Quarter Operating Results, Declares Regular Quarterly Cash Dividend, Discusses Fiscal 2004 Dividends and Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 18, 2003--Meridian Bioscience,
Inc. (Nasdaq:VIVO)
HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today:
reported record fiscal 2003 net sales of $65.9 million (up 11%
over fiscal 2002) and diluted earnings per share of $0.47 (up
38% over fiscal 2002) and at the upper range of management's
guidance;
reported record fourth quarter fiscal 2003 net sales of $17.2
million (up... |
| | | 11/12/03 | Meridian Bioscience Announces Exchange Offer for and Plans to Redeem 7% Convertible Subordinated Debentures Due 2006| CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2003--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has
commenced an offer to exchange $16.0 million principal amount of new
Convertible Subordinated Debentures due 2013 for an equal principal
amount of its outstanding 7% Convertible Subordinated Debentures due
2006. The new debentures will bear interest at 5% per year, payable
semi-annually each March 1 and September 1. The principal amount of
the new debentures wi... |
| | | 10/15/03 | Meridian Bioscience Recognized as One of Forbes' 200 Best Growth Companies in America| CINCINNATI--(BUSINESS WIRE)--Oct. 15, 2003--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Forbes has
recognized it as one of the "200 Best Growth Companies in America", as
reported in their October 27, 2003 edition.
The Forbes 200 Best Growth Companies in America list is selected
from a database of 3,500 candidates whose last 12-month sales range
between $5 million and $600 million. Additional qualification criteria
included profitability tests and l... |
| | | 10/06/03 | Meridian Bioscience Awarded Contract to Manufacture Parvovirus Vaccine for National Institutes of Health - NIH| CINCINNATI--(BUSINESS WIRE)--Oct. 6, 2003--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has been
awarded a contract to manufacture clinical grade recombinant protein
Parvovirus B19 vaccine for The National Institutes of Health. Vaccine
production will take place at the Company's life science manufacturing
facility located at Viral Antigens, Inc. (VAI), Memphis, TN, a wholly
owned subsidiary. Under the terms of this contract, National Heart,
Lung, and B... |
| | | 09/26/03 | Meridian Bioscience Files Shelf Registration Statement| CINCINNATI--(BUSINESS WIRE)--Sept. 26, 2003--Meridian Bioscience,
Inc. (NASDAQ:VIVO) today announced that it has filed a universal shelf
registration statement with the Securities and Exchange Commission
registering an aggregate of $60 million of securities, which includes
common stock, preferred stock, debt or other types of securities. The
Company stated that it believes this universal shelf registration
statement will facilitate its ability to finance its growth strategies
through the ... |
| | | 07/31/03 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2004| CINCINNATI--(BUSINESS WIRE)--July 31, 2003--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today provided the financial community with
guidance regarding the Company's fiscal 2004 sales and earnings
estimates. Based on the Company's business planning and budgeting
activities, for the fiscal year ending September 30, 2004, management
expects net sales to be in the range of $71 to $75 million and per
share diluted earnings to be between $0.47 and $0.53. The per share
estimates assume an increase i... |
| | | 07/30/03 | Meridian Bioscience to Present at Robert W. Baird & Co.'s 2003 Small Cap Conference| CINCINNATI--(BUSINESS WIRE)--July 30, 2003--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief
Executive Officer; Jack Kraeutler, President and Chief Operating
Officer; and Rick Eberly, Executive Vice President and General
Manager, Meridian Life Science, have been invited to present at the
Robert W. Baird 2003 Small Cap Conference Tuesday, August 5, 2003 at
10:45 a.m. EDT at the Four Seasons Hotel in New York City. A question
and answer session wil... |
| | | 07/24/03 | Meridian Bioscience Reports Third Quarter Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance| CINCINNATI--(BUSINESS WIRE)--July 24, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO)
Meridian Bioscience, Inc., (Nasdaq:VIVO) today:
reported record third quarter sales of $15,693,000, a 5%
increase over the same period of the prior fiscal year;
reported diluted earnings per share of $0.12, a 9% increase
over the same period of the prior fiscal year;
reported third quarter operating income of $3,068,000, second
highest third quarter earnings in ... |
| | | 07/21/03 | Meridian to Manufacture and Distribute Chagas' Disease Proteins Under License Agreement with Corixa Corporation| CINCINNATI--(BUSINESS WIRE)--July 21, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it will begin production of
recombinant Trypanosoma cruzi (Chagas' disease) antigen under a
license agreement with Corixa Corporation (Nasdaq:CRXA) in its life
science production laboratories located at Viral Antigens, Inc.,
Memphis, TN (VAI), a wholly owned subsidiary. The unique recombinant
polyvalent antigen, known as TcF, will be marketed to diagnostic test
manufacturers for use i... |
| | | 07/01/03 | Meridian Bioscience Added to Russell 2000 Index| CINCINNATI--(BUSINESS WIRE)--July 1, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has been added to the
Russell 2000(R) Index of small-capitalization stocks. The Russell
Indexes were jointly developed by the Frank Russell Company and the
New York Futures Exchange to represent investment-grade equities.
Meridian's inclusion in the Russell Index is a result of the Frank
Russell Company's annual assessment and reconstitution of its U.S.
equity indexes. Final a... |
| | | 06/10/03 | Meridian Announces Manufacturing Agreement with Hawaii Biotech, Inc. to Produce Vaccine for Dengue Fever| CINCINNATI--(BUSINESS WIRE)--June 10, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced the signing of its second
biopharmaceutical manufacturing agreement for the Company's life
science production facility located at Viral Antigens, Inc., Memphis,
TN (VAI), a wholly-owned subsidiary. Hawaii Biotech, Inc. has selected
VAI to manufacture and supply bulk polyvalent recombinant subunit
vaccine for dengue virus 1-4. The bulk vaccine for human clinical
studies will be produced in ... |
| | | 04/24/03 | Meridian Bioscience Reports Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance| CINCINNATI--(BUSINESS WIRE)--April 24, 2003--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today:
reported all-time record quarterly sales of $16,913,000, a 12%
increase over the same period of the prior fiscal year;
reported diluted earnings per share of $0.13, a 30% increase
over the same period of the prior fiscal year;
reported all-time record quarterly operating income of
$3,784,000;
declared a regular cash dividend of $... |
| | | 04/09/03 | Meridian Announces First Manufacturing Agreement for Its New Life Science Production Facility and Names Richard Eberly Head of Newly Established Life Science Business Unit| CINCINNATI--(BUSINESS WIRE)--April 9, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has signed its first
manufacturing agreement for the Company's new cGMP life science
production facility located at Viral Antigens, Inc., Memphis, TN
(VAI), a wholly owned subsidiary. Under the terms of the agreement,
VAI will optimize manufacturing processes and produce a specific
insect cell-derived recombinant protein for its contract partner. This
recombinant protein will be VA... |
| | | 03/24/03 | Japanese Multicenter Study of Meridian HpSA -- Stomach Ulcers -- Test Supports Usefulness in Diagnosing Pediatric Infections| CINCINNATI, Mar 24, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today announced the publication, in The American Journal of
Gastroenterology, of an important multicenter clinical study of Meridian's
Premier Platinum HpSA(R) Test (HpSA) conducted in leading childrens' hospitals
in Japan. The study, performed by the Japanese Pediatric HpSA Study Group, was
designed to evaluate the diagnostic accuracy of Meridian's HpSA test in Japanese
children. Based upon the results of... |
| | | 02/19/03 | Dr. K. John Morrow, Jr., Noted Geneticist and Molecular Biologist, Joins Meridian Bioscience, Inc.| CINCINNATI, Feb 19, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc.,
Cincinnati, Ohio (Nasdaq:VIVO) today announced that Dr. K. John Morrow, Jr. has
joined its expanding scientific team. Prior to Meridian, Dr. Morrow was
Professor of Cell Biology and Biochemistry at Texas Tech University Health
Sciences Center in Lubbock, Texas. Dr. Morrow's research expertise is in the
field of genetics and molecular systems for immunology. His current research is
in the area of genetically engineered a... |
| | | 01/21/03 | Meridian Bioscience Reports Record Sales and Record First Quarter Operating Income, Declares Higher Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance|
BIOWIRE2K
CINCINNATI--(BUSINESS WIRE)--Jan. 21, 2003--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today:
reported record quarterly net sales of $16,103,000
resulting in net earnings of $1,424,000 ($0.10 per diluted
share) for the first quarter ended December 31, 2002: net
sales were an all time record for any quarter in the
Company's history;
declared a regular quarterly cash dividend of $0.09 per
share, $0.02 per share higher (+29%) tha... |
| | | 01/15/03 | Meridian Awarded New Patent for Novel Transport Device|
CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2003--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has received from the U.S.
Patent and Trademark Office the official Notice of Allowance for a
patent entitled "Biological Sampling and Storage Container Utilizing a
Desiccant". The patent relates to a device for the sampling and
storing of specific biological samples used in medical testing. This
allowance compliments a patent that was granted earlier (Patent No.
6,29... |
| | | 01/09/03 | Meridian's E. Coli Toxin Test Granted New Claim|
BIOWIRE2K
CINCINNATI--(BUSINESS WIRE)--Jan. 9, 2003--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has been
granted FDA clearance to market an additional claim related to its
ImmunoCard STAT!(R) E. coli 0157 Plus. This test identifies the most
dangerous Shiga toxin-producing E. coli bacteria that can cause severe
kidney damage or death, especially in infected children under 5 years
of age. This new claim will enable the toxin-pro... |
| | | 11/19/02 | Meridian Bioscience Announces Dividend Actions and Provides Guidance for Fiscal 2003|
BIOWIRE2K
CINCINNATI--(BUSINESS WIRE)--Nov. 19, 2002--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today (i) declared the regular cash dividend for
the fourth quarter ended September 30, 2002, (ii) increased the
regular cash dividend rate for fiscal 2003, and adopted a new cash
dividend policy; and (iii) provided guidance to the financial
community with respect to its operating projections for the current
fiscal year ending September 30, 2003 as follows:
Fisca... |
| | | 11/13/02 | Meridian Bioscience Reports Fiscal 2002 Year End and Fourth Quarter Operating Results|
BIOWIRE2K
CINCINNATI--(BUSINESS WIRE)--Nov. 13, 2002--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today reported operating results
for the fourth quarter and fiscal year ended September 30, 2002.
Fiscal Year 2002
Net sales for fiscal 2002 were $59,104,000 as compared to
$56,527,000 for fiscal 2001, an increase of $2,577,000 or 4.6%. Net
income for fiscal 2002 was $5,031,000, $0.34 per diluted share,
compared to a loss of $10,275,0... |
| | | 11/08/02 | Meridian Bioscience and Biotrin Holdings Terminate Acquisition Talks|
BIOWIRE2K
CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2002--Meridian Bioscience,
Inc.,(Nasdaq:VIVO) today announced that it and Biotrin Holdings plc
have terminated negotiations and ceased further discussions regarding
Meridian Bioscience's earlier interest in acquiring Biotrin Holdings.
Meridian is a fully integrated life science company that
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related pr... |
| | | 10/07/02 | Meridian Reports on Biotrin Progress| CINCINNATI, Oct 7, 2002 (BUSINESS WIRE) -- Meridian Bioscience, Inc.
(Nasdaq:VIVO) today announced it is continuing its pre-acquisition due diligence
review of Biotrin Holdings plc, an Irish-based diagnostics company, and is
concurrently in the process of negotiating a definitive stock purchase
agreement. Although there can be no assurances that this previously announced
contemplated acquisition will take place, progress is being made and it is
anticipated that the purchase of Biotrin will... |
| | | 07/23/02 | Meridian Reports Profitable Third Quarter Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2002 Guidance and Comments On Other Subjects| CINCINNATI, Jul 23, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO)
EPS of $0.11 reported for the third quarter of fiscal year
2002 compared to ($0.04) in the prior year period
EPS of $0.28 reported for the first nine months of fiscal year
2002 compared to ($0.72) in the prior year period
Fiscal year 2002 EPS estimate of $0.38 to $0.43 reaffirmed
Strong EBITDA and positive cash flow in fiscal year 2002
Bi... |
| | | 07/22/02 | Meridian Commences Distribution of New Rapid Test for Stomach Ulcers| CINCINNATI, Jul 22, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today announced that it has begun international distribution of
its patent protected ImmunoCard Stat! HpSA rapid test for Helicobacter pylori
bacteria, the primary cause of stomach ulcers. The ImmunoCard STAT! HpSA test is
highly accurate, simple to perform, and yields results in just five minutes. The
speed and simplicity of the test makes it ideal for use in quickly diagnosing,
treating and monitoring su... |
| | | 07/18/02 | Meridian Announces Japanese Market Launch of Rapid Adenovirus Test| CINCINNATI, Jul 18, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.,
Cincinnati, Ohio (Nasdaq:VIVO) today announced that its Japanese distributor,
TFB, Inc. of Tokyo, Japan has begun distribution of Meridian's ImmunoCard
STAT!(R) Adenovirus test, having received approval to market by the Japanese
Ministry of Health. ImmunoCard STAT! Adenovirus is a rapid point-of-care test
that can be used in a physician's office to directly detect the virus that can
cause conjunctivitis, pharyngitis, or... |
| | | 05/23/02 | Meridian Signs Agreement in Principle to Acquire Biotrin Holdings plc|
CINCINNATI--(BW HealthWire)--May 23, 2002--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced it has executed a letter of intent
to acquire all the outstanding capital stock of Biotrin Holdings plc,
headquartered in Dublin, Ireland.
The purchase price includes cash and possible future earnout
opportunities, the amounts of which were not disclosed. The
transaction is expected to be completed within 45 days.
Biotrin develops, manufactures and sells lead... |
| | | 05/14/02 | Meridian Appoints PricewaterhouseCoopers LLP as Its Independent Public Accountants| CINCINNATI, May 14, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.
(Nasdaq:VIVO) today announced that it has appointed PricewaterhouseCoopers LLP
as the Company's Independent Certified Public Accountants for fiscal year 2002.
This appointment is the culmination of an extensive two-month evaluation and
selection process involving the Audit Committee of the Board of Directors and
executive management.
William J. Motto, Chairman and Chief Executive Officer, stated, "We believe the
Pric... |
| | | 04/23/02 | Meridian Reports Profitable Second Quarter Results, Declares Regular Cash Dividend, Reaffirms Fiscal 2002 Guidance and Comments On Other Subjects| CINCINNATI, Apr 23, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.
(Nasdaq:VIVO):
Second quarter EPS of $0.10 reported
First half EPS of $0.18 reported
Full year EPS of $0.38 to $0.43 reaffirmed
Record EPS for fiscal 2003 expected
Strong EBITDA and positive cash flow
Fully funded internal business plan
Solid financial condition
No impairment charges under SFAS 142
Life science progress
Acquisition search underw... |
| | | 03/28/02 | Meridian's Patented Premier HpSA Stomach Ulcer Test Subject of Article in Annals of Internal Medicine| CINCINNATI, Mar 28, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.
(Nasdaq:VIVO) today announced that an important drug eradication study of its
Premier HpSA(R) (stomach ulcer) test has been published in an article entitled,
"The Stool Antigen Test for Detection of Helicobactor pylori after Eradication
Therapy," (Dr. D. Vaira, Dr. N. Vakil, et al.).
Appearing in the February 19, 2002, issue of the Annals of Internal Medicine,
the article reports on a study designed to determine wheth... |
| | | 01/22/02 | Meridian Bioscience Reports Favorable First Quarter Operating Results, Declares Regular Cash Dividend, and Reaffirms EPS Guidance for Fiscal 2002| CINCINNATI, Jan 22, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today announced net earnings of $1,187,000, or $0.08 per fully
diluted share for the first quarter ended December 31, 2001.
This compares with a net loss of $8,192,000, or $0.56 per share for the same
period of the prior fiscal year. Net sales for the first quarter of this fiscal
year were $13.6 million compared to $15.3 million for the first quarter of the
prior fiscal year, a decline of approximately ... |
| | | 01/09/02 | Meridian Bioscience's Helicobacter pylori -- Stomach Ulcers -- Technology Granted European Patent| CINCINNATI, Jan 9, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today announced that it has been granted a patent in Europe
covering its innovative technology for detecting the primary causative agent for
stomach ulcers, Helicobacter pylori. This technology, which is the basis for the
Premier Platinum HpSA(TM) test, was granted the first of its United States'
patents in February 1998.
Premier Platinum HpSA was the first noninvasive direct test for Helicobacter
pylor... |
| | | 01/07/02 | Meridian Announces April 2002 Availability of Its Biopharmaceutical Production Facilities| CINCINNATI, Jan 7, 2002 (BW HealthWire) -- Meridian Bioscience, Inc.,
Cincinnati, Ohio (Nasdaq:VIVO), today announced that its wholly-owned subsidiary
Viral Antigens, Inc. (VAI), has initiated a marketing campaign, based upon
direct mail, personal contacts and an upgraded website (www.viralantigens.com),
designed to communicate the anticipated availability of its new
biopharmaceutical production laboratories. The Memphis, Tenn.-based VAI is
combining 20 years of cell culture expertise with... |
| | | 12/17/01 | Meridian Bioscience Reaffirms Sales and Earnings Guidance and Provides Other Information|
CINCINNATI--(BW HealthWire)--Dec. 17, 2001--Meridian Bioscience,
Inc., (Nasdaq:VIVO)
This fiscal year earnings guidance of $0.38 to $0.43 per
share, fully diluted
First quarter earnings guidance of $0.07 to $0.08 per share,
fully diluted
Viral Antigens expansion - capital expenditure - key growth
strategy
Fully funded business plan - sound balance sheet - positive
cash flow
Cash dividend rate recently i... |
| | | 11/20/01 | Meridian Bioscience Expands Product Introduction to the Japanese Healthcare Market|
CINCINNATI--(BW HealthWire)--Nov. 20, 2001--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that its
Japanese distributor, TFB, Inc. of Tokyo, Japan, filed a request to
market Meridian's ImmunoCard STAT!(R)Adenovirus test with the Japanese
Ministry of Health. ImmunoCard STAT! Adenovirus is a rapid
point-of-care test for direct detection of the virus that can cause
conjunctivitis, pharyngitis, or gastrointestinal disease. The test is
simple to perform and pr... |
| | | 11/14/01 | Meridian Bioscience Declares Regular Cash Dividend, Increases Regular Cash Dividend Rate and Reaffirms Sales and Earnings Guidance for Fiscal 2002| CINCINNATI, Nov 14, 2001 (BW HealthWire) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today (i) declared the regular cash dividend for the fourth
quarter ended September 30, 2001; (ii) increased the regular cash dividend rate
for fiscal 2002; and reaffirmed sales and earnings per share guidance for fiscal
2002, as follows:
Fiscal 2001 Fourth Quarter Regular Cash Dividend
The Board of Directors declared the regular quarterly cash dividend of $0.065
per share for the fourth qua... |
| | | 11/14/01 | Meridian Reports Fiscal 2001 Year End and Profitable Fourth Quarter Operating Results| CINCINNATI, Nov 14, 2001 (BW HealthWire) -- Meridian Bioscience, Inc.
(Nasdaq:VIVO) today reported operating results for the fourth quarter and for
the fiscal year ended September 30, 2001.
Fourth Quarter Operating Results
Net earnings for the fourth fiscal quarter ended September 30, 2001, were
$171,000, or $0.01 per share. Net sales for the fourth fiscal quarter were
$13,501,000 compared to $13,850,000 for the same period of the prior fiscal
year, a decrease of $349,000 or... |
| | | 11/08/01 | Meridian Announces Agreements With Thermo Electron Corporation for the Immediate Distribution of Infectious Disease Tests for Influenza, C. difficile, E. coli and Rotavirus| CINCINNATI, Nov 8, 2001 (BW HealthWire) -- Meridian Bioscience, Inc.,
Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has signed two agreements
for the distribution of important infectious disease tests with Thermo Electron
Corporation (NYSE:TMO)
Under the terms of the agreements, Meridian will immediately begin marketing
Thermo Electron's new point-of-care tests for influenza and C. difficile in the
U.S. These test kits utilize Thermo Electron's Thermo Biostar proprietary
Optic... |
| | | 10/22/01 | Meridian Announces Distribution Agreement With ScheBo Biotech AG for the Distribution in Italy of a Novel Test for Pancreatic Dysfunction| CINCINNATI, Oct 22, 2001 (BW HealthWire) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today announced that it's subsidiary Meridian Bioscience Europe
Srl., has signed a Distribution Agreement with ScheBo(R)Biotech AG, a fast
growing German biotechnology company, to market ScheBo Pancreatic Elastase-1
Stool Test, a non-invasive, novel test for the detection and quantification of
human pancreatic elastase-1.
Pancreatic Elastase-1 is an indicator of pancreatic exocrine insufficiency,
which... |
| | | 10/09/01 | Meridian Bioscience Provides Guidance for Fiscal 2002 and Reports On Capital Adequacy and Other Matters|
CINCINNATI--(BW HealthWire)--Oct. 9, 2001--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today provided guidance to the financial community
with respect to its operating projections for the current fiscal year
ending September 30, 2002.
Based on Meridian's recently completed business planning and
budgeting activities, management expects net sales to be in the range
of $62 -- $65 million and fully diluted earnings per share of between
$0.38 and $0.43 for fiscal 2002.
... |
| | | 08/16/01 | Broadlane Awards Contract to Meridian Bioscience| CINCINNATI, Aug 16, 2001 (BW HealthWire) -- Meridian Bioscience, Inc.
(Nasdaq:VIVO) today announced it has been awarded a three-year contract from
Broadlane Inc., a leader in delivering supply chain services to the healthcare
industry.
The contract includes Meridian's full line of parasitological transport devices
and several of its microbiological diagnostic products used in the detection of
gastrointestinal, bacterial, and parasitic infections. Meridian's newest product
for the detec... |
| | | 07/24/01 | Meridian Reports Profitable Third Quarter Operating Results and Declares Regular Cash Dividend|
CINCINNATI--(BW HealthWire)--July 24, 2001--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today reported operating results
for the third quarter and for the nine months ended June 30, 2001 and
declared the regular cash dividend, as follows:
Third Quarter Operating Results
Net sales for the third fiscal quarter ended June 30, 2001, were
$13,906,000 as compared to $14,340,000 for the same period of the
prior fiscal year, a decrease of $434,000 or 3%. Ex... |
| | | 06/07/01 | Meridian Announces First Preview of UPlink Technology At 2001 American Society of Microbiology Meeting| CINCINNATI, Jun 7, 2001 (BW HealthWire) -- Meridian Bioscience, Inc.,
(Nasdaq:VIVO) today announced that its highly sensitive, novel UPlink(TM)
technology was previewed in a poster session at the 2001 American Society for
Microbiology Conference, held in Orlando, FL.
Meridian and its partner, OraSure Technologies, Inc., demonstrated, for the
first time, the unique abilities of the phosphor-based UPlink technology in the
detection of infectious disease. Meridian and OraSure have an exclu... |
| | | 05/29/01 | Meridian Bioscience Hires Vice President of Regulatory Affairs and Quality Systems|
CINCINNATI--(BW HealthWire)--May 29, 2001--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced it has hired Susan Rolih as its
Vice President of Regulatory Affairs and Quality Systems. Most
recently, Ms. Rolih was Corporate Vice President - Regulatory Affairs
and Quality Assurance at Immucor, Inc., Norcross, GA. She previously
held titles of Vice President-Regulatory Affairs and Quality Assurance
and Vice President-Technical Services. Ms. Rolih has extensive
experience in manag... |
| | | 05/22/01 | Meridian Bioscience Reports On Profitable Operations, Increased Production and Plans to Expand Credit Facility|
CINCINNATI--(BW HealthWire)--May 22, 2001--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced operating results for the month of
April were profitable, consistent with the Company's earlier public
statements that it expected operating results would become profitable
during the current quarter. Quoting from the April 24, 2001, press
release, "Notwithstanding the operating losses reported for the second
quarter and first half of fiscal 2001, meaningful progress has been
made in i... |
| | | 05/14/01 | Meridian Announces Patent Filing Describing the Correlation of Colic and H. pylori Infection in Infants|
CINCINNATI--(BW HealthWire)--May 14, 2001--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced that it has filed both a U.S.
Patent Application and an International Application under the Patent
Cooperation Treaty directed to the diagnosis of Helicobacter pylori
(H. pylori) associated colic in infants and its treatment with
antibiotic and other therapies. H. pylori infection has also been
implicated in gastroduodenal diseases such as peptic ulcers,
gastritis, and stomach cancer.... |
| | | 04/24/01 | Meridian Reports Second Quarter Results, Declares Regular Cash Dividend and Announces Stock Buyback Program|
CINCINNATI, Ohio--(BW HealthWire)--April 24, 2001--Meridian
Bioscience, Inc. (Nasdaq:VIVO), today reported operating results for
the second quarter and six months ended March 31, 2001, declared the
regular cash dividend and announced a stock buyback plan, as follows:
Second Quarter Operating Results
Net sales for the second fiscal quarter ended March 31, 2001, were
$13,866,000 as compared to $14,577,000 for the same period of the
prior fiscal year, a decrease of ... |
| | | 04/12/01 | Meridian Bioscience Launches Rapid One-Step Test for Direct Detection of Cryptosporidium and Giardia|
CINCINNATI--(BW HealthWire)--April 12, 2001--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has
launched a new rapid, one-step device for the simultaneous detection
of two waterborne parasites, Giardia and Cryptosporidium.
ImmunoCard STAT!(R) Cryptosporidium/Giardia, gives accurate,
easy-to-read results in just minutes.
Giardia lamblia and Cryptosporidium are waterborne parasites
causing acute diarrhea and gastrointestinal dist... |
| | | 04/02/01 | Meridian Bioscience Hires Vice President of Operations|
CINCINNATI--(BUSINESS WIRE)--April 2, 2001--Meridian Bioscience,
Inc., (Nasdaq:VIVO) today announced it has hired Larry Baldini as its
Vice President of Operations. Most recently, Mr. Baldini was Director
of Operations (Sensory Systems) at Instrumentation Laboratories, Ann
Arbor, MI; he previously held the titles of Operations Manager and
Facilities Manager. Mr. Baldini has extensive experience in managing a
wide variety of operations, including implementing quality systems
(QSRs an... |
| | | 03/28/01 | Meridian Bioscience Announces Important Supply Contract and Comments on Return to Profitable Operations and Capital Adequacy|
CINCINNATI--(BW HealthWire)--March 28, 2001--Meridian Bioscience,
Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced it has entered
into a long-term supply agreement with Zeus Scientific, Inc. for
27 products to be marketed under the Meridian Bioscience brand name.
Zeus Scientific, headquartered in Raritan, New Jersey, is a
well-established and highly regarded developer and producer of
infectious disease serology products. The launch date for the
Zeus-manufactured, Meri... |
| | | 02/09/01 | Meridian Announces Fiscal Year 2001 First Quarter Results|
CINCINNATI--(BW HealthWire)--Feb. 9, 2001--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced net sales for the first fiscal
quarter that ended December 31, 2000, of $15,254,000 compared to
$14,329,000 for the corresponding period of the prior fiscal year.
Meridian reported a net loss of ($8,192,000) or ($0.56) per share
for the first quarter of fiscal 2001, reflecting charges for its
European restructuring plan ($657,000, after tax) and other charges of
($8,500,000, ... |
| | | 01/24/01 | Meridian Announces Name Change and Declares Dividend for First Quarter|
CINCINNATI--(BW HealthWire)--Jan. 24, 2001--Meridian Bioscience,
Inc. (Nasdaq:VIVO) today announced that yesterday shareholders
formally approved Meridian's name change.
Henceforth, the Company will be Meridian Bioscience, Inc. and
trade under the symbol VIVO. Meridian's Board of Directors declared a
dividend of $0.065 per share to be paid February 8, 2001 to
shareholders of record as of February 1, 2001. The regular quarterly
cash dividend is at an indicated annual rate o... |
| | | 01/08/01 | Meridian Diagnostics, Inc., dba Meridian Bioscience, Inc. Announces Ticker Symbol Change|
CINCINNATI--(BW HealthWire)--Jan. 8, 2001--Meridian Bioscience,
Inc. today announced that effective with commencement of trading
tomorrow morning, the Nasdaq ticker symbol for its common stock will
be VIVO.
As mentioned in the Company's annual report to shareholders,
Meridian has moved rapidly beyond its original mission as a
manufacturer and distributor of high-quality diagnostic test kits. Our
strategies have been broadened to encompass participation in the
rapidly evol... |
| | | 11/16/00 | Meridian Diagnostics, Inc. Announces Fiscal Year 2000 Operating Results|
CINCINNATI--(BW HealthWire)--Nov. 16, 2000--Meridian Diagnostics,
Inc. (Nasdaq:KITS)
Meridian Diagnostics, Inc.
Reports fiscal year 2000 per share earnings of $0.49 vs. $0.14
Undertakes European restructuring
Announces planned name and NASDAQ symbol change to reflect
expanding business capabilities
Declares regular cash dividend and increases indicated rate
for fiscal 2001
O... |
| | | 11/14/00 | Meridian Diagnostics, Inc. Invites You to Participate in its Conference Call to discuss Fiscal Year 2000 Earnings on Thursday, November 16, 2000 at 3:00 p.m. ET|
CINCINNATI--(BW HealthWire)--Nov. 14, 2000--Meridian Diagnostics,
Inc. (Nasdaq:KITS) expects to release Fiscal Year 2000 earnings on
Thursday, November 16, 2000. There are two alternative communication
modes available for you to listen to the call.
Option No. 1
------------
Over the Telephone
Call 1-800-491-3423 (domestic) or 303-267-1007 (international),
Conference ID 859812.
If you plan to participate in the conference call via the telephone,
please RSVP to Meridi... |
| | | 11/01/00 | Meridian Diagnostics, Inc. Appoints New Director to its Board|
CINCINNATI--(BW HealthWire)--Nov. 1, 2000--Meridian Diagnostics,
Inc., (Nasdaq:KITS) today announced that it has appointed David C.
Phillips to the Company's Board of Directors, effective immediately.
The appointment of Mr. Phillips fills a vacant seat on the Board that
has been open since July 1999.
Mr. Phillips was with the international accounting firm of Arthur
Andersen for 32 years and served in a variety of positions prior to
his retirement as firm-wide Managing Part... |
| | | 10/18/00 | Meridian Diagnostics Recognized as One of Forbes 200 Best Small Companies|
CINCINNATI--(BW HealthWire)--Oct. 18, 2000--Meridian Diagnostics,
Inc., Cincinnati, Ohio (Nasdaq:KITS) today announced that it has been
recognized as one of the "Forbes 200 Best Small Companies" as reported
in the October 17, 2000 issue of Forbes magazine.
The Forbes 200 Best Small Companies list is selected following a
comprehensive evaluation of financial results plus additional
operating factors of candidate companies having sales between
$5 million and $350 million. A... |
| | | 09/27/00 | Meridian Diagnostics Expands Research Partnership with Texas Tech University and Completes Acquisition of Viral Antigens|
CINCINNATI, Sept. 27 /PRNewswire/ -- Meridian Diagnostics, Inc.
(Nasdaq: KITS) today announced that it has entered into an expanded research
agreement with Texas Tech University Health Sciences Center (Lubbock, TX) and
Dr. K. John Morrow, Jr. for the development of highly specific, gene-mediated
antigen and antibody systems. This project is expected to yield more specific
and sensitive biologicals for use in diagnosing and treating disease. Morrow
and his Texas Tech collaborato... |
| | | 09/14/00 | Meridian Signs Agreement to Acquire Viral Antigens, Inc.|
CINCINNATI--(BW HealthWire)--Sept. 14, 2000--Meridian Diagnostics,
Inc. (Nasdaq:KITS)
Leading producer of highly specialized biologicals
Expands Meridian's biotechnology capabilities
Technology rich, strong proprietary know-how
Highly profitable, sound balance sheet
Accretive earnings expected
Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today
announced it has executed de... |
| | | 08/30/00 | Meridian Signs Major Agreement for Advanced Technology Development|
CINCINNATI--(BW HealthWire)--Aug. 30, 2000--Meridian Diagnostics,
Inc. (NASDAQ:KITS) today announced that it has entered into exclusive
long-term Research, Development and Supply Agreements with STC
Technologies, Inc. Bethlehem, PA for a highly sensitive proprietary
multi-test diagnostic system. The scope of these agreements includes
the development, manufacturing, and sale of a broad range of rapid
tests for the detection of infectious diseases including, but not
limited to, parasi... |
| | | 08/28/00 | Meridian Announces Major Expansion of Its Biotechnology Resources|
CINCINNATI--(BW HealthWire)--Aug. 28, 2000--
Leveraging of Meridian's antibody capabilities
Collaboration with university, biotech, and pharmaceutical
partners
Use of genomic and proteomic science
Novel drug and vaccine discovery support, and related diagnostic
assays
Meridian Diagnostics, Inc., (NASDAQ: KITS) today announced an
expansion of its capabilities in biotechnology, research reagent
developme... |
| | | 07/21/00 | Meridian Diagnostics Announces Record Third Quarter and Nine Months Operating Results and Declares Regular Cash Dividend|
CINCINNATI--(BW HealthWire)--July 21, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS)
After restating 1999 for a nonmaterial bookkeeping error:
Third quarter sales, excluding the impact of currency,
increased 9%
Third quarter net earnings increased 72%
Third quarter EBITDA increased 40%
Net income for the first 9 months increased 79%
EBITDA for the first 9 months increased 41%
Gull Salt Lake City facility sold
Meridi... |
| | | 04/20/00 | Meridian Diagnostics Announces Record Earnings| Second quarter net earnings increased 47%
Second quarter EBITDA increased 28%
Net income for the first 6 months increased 84%
EBITDA for the first 6 months increased 44%
CINCINNATI--(BW HealthWire)--April 20, 2000--Meridian
Diagnostics, Inc. (Nasdaq:KITS)
Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced that
net earnings for the second quarter of this fiscal year were a record $1,849,000, or $0.13 per share, compared to $1,256,... |
| | | 04/06/00 | New Study Reports Genital Herpes Can Be Spread By Asymptomatic Individuals|
CINCINNATI--(BW HealthWire)--April 6, 2000--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced a recently published study has determined that individuals infected with genital herpes, usually HSV Type 2, can spread the virus to others even when symptoms are not present. This research, published in the New England Journal of Medicine and conducted by Dr. Anna Wald, medical director of the University of Washington's Virology Research Clinic, indicated that infected ... |
| | | 03/21/00 | Meridian Diagnostics Acquires Technology & Marketing Rights From La Jolla Diagnostics for Rapid Tuberculosis -- TB -- Test|
CINCINNATI--(BW HealthWire)--March 21, 2000--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) and La Jolla Diagnostics (LAJD) today announced an agreement for an undisclosed cash payment and future royalties for a unique rapid blood test for active tuberculosis from the DiagnosTech subsidiary of La Jolla Diagnostics, Inc. The test utilizes a combination of three highly specialized Mycobacterium tuberculosis antigens that will react with blood serum from persons having active TB... |
| | | 02/22/00 | Meridian Receives FDA Clearance To Market Premier C. difficile Toxins A&B| CINCINNATI--(BW HealthWire)--Feb. 22, 2000--Meridian Diagnostics,
Inc., (Nasdaq:KITS) today announced that it has received clearance from the United States Food and Drug Administration (FDA) to market Premier™ C. difficile Toxins A&B, the sixth member of the company's C. difficile product family.
Toxigenic C. difficile is the major cause of Antibiotic Associated Diarrhea (AAD) and Antibiotic Associated Pseudo-membranous Colitis (PMC), two serious conditions that can ... |
| | | 01/21/00 | Meridian's Board of Directors Declares Dividend for First Quarter Operating Results|
CINCINNATI--(BW HealthWire)--Jan. 21, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced that the Board of Directors declared a dividend of $0.06 per share to be paid February 8, 2000 to shareholders of record as of February 1, 2000.
The regular quarterly cash dividend is at an indicated annual rate of $0.24 per share, an increase of 20% over the prior year's annual rates. Yesterday, Meridian announced record first quarter operating results with net sales increasi... |
| | | 01/20/00 | Meridian Announces Record First Quarter Operating Results|
CINCINNATI--(BW HealthWire)--Jan. 20, 2000--Meridian Diagnostics, Inc. (Nasdaq:KITS)
Net sales increased 22%
Net earnings increased 165%
EBITDA increased 44%
Record fiscal year expected
Meridian Diagnostics, Inc. (Nasdaq:KITS) today announced net
sales for the first fiscal quarter, which ended December 31, 1999, of $14,329,000 compared to $11,720,000 for the same period of the prior fiscal year. Net earnings for the firs... |
| | | 11/17/99 | Meridian Diagnostics Reports Year-End Operating Results and Increases Dividend Rate|
CINCINNATI--(BW HealthWire)--Nov. 17, 1999--Meridian Diagnostics, Inc. (Nasdaq:KITS)
Net sales increased 64%
Per share earnings of $0.42 before non-recurring merger
integration and purchased research and development costs
EBITDA of $12.3 million
Annual cash dividend rate increased 20% to $0.24 per share based
on strong business outlook for and expectation of record net
income for fiscal 2000
Meridian Diagnostics, Inc. (Nasdaq:KIT... |
| | | 10/22/99 | HCFA Announces Coverage of Meridian Diagnostics New Ulcer Test|
CINCINNATI--(BW HealthWire)--Oct. 22, 1999--Meridian Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today reported that the United States Health Care Financing Administration (HCFA) has announced their national coverage policy decision relating to Meridian Diagnostics' new non-invasive ulcer test, Premier Platinum HpSA(TM)(HpSA).
The purpose of the HpSA test, which was cleared by the Food and Drug Administration (FDA) to market in May 1998, is to aid in the diagnosis of H... |
| | | 09/28/99 | Meridian's Stomach Ulcer Test Unaffected by Common Medications|
CINCINNATI--(BW HealthWire)--Sept. 28, 1999--Meridian
Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq: KITS) today announced
that The American Journal of Gastroenterology (AJG) published an
article entitled, ''Effects of Acid Suppression and Bismuth Medications
on the Performance of Diagnostic Tests for Helicobacter pylori
Infection,'' (Luis E. Bravo, M.D., et. al.). This article reports on a
study designed to investigate whether acid suppression and bismuth
medications interfere with the... |
| | | 08/11/99 | Meridian's New Rapid Test for E. coli Infections Receives FDA Clearance to Market| CINCINNATI--(BW HealthWire)--Aug. 11, 1999--Meridian Diagnostics,
Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that it has
received clearance from the United States Food and Drug Administration
(FDA) to market ImmunoCard STAT!(TM) E. coli O157 Plus.
This rapid test will detect the most prevalent toxigenic strain
of E. coli, E. coli O157:H7, which is often transmitted via ground
beef, vegetables and other foods. E. coli O157 infects up to 1 million
individuals each year in the U... |
| | | 07/22/99 | Meridian Diagnostics Announces Third Quarter and Nine Months Operating Results, Reports Operations At Gull Laboratories Continue to Exceed Expectations, Declares Dividend| CINCINNATI--(BW HealthWire)--July 22, 1999--Meridian Diagnostics,
Inc. (Nasdaq:KITS) today announced net sales of $13,825,000 for the
third fiscal quarter ended June 30, 1999, compared to net sales of
$8,226,000 for the same period of the prior fiscal year, an increase
of $5,599,000, or 68%. Net earnings, excluding the after-tax impact of
merger integration costs of $339,000 ($0.03 per share) in connection
with the recent acquisition of Gull Laboratories, were $1,684,000 or
$0.12 per shar... |
| | | 07/14/99 | Meridian Test Aids in Diagnosis of Toxic E. coli Outbreak| CINCINNATI--(BW HealthWire)--July 14, 1999--Meridian
Diagnostics, Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced
that its Premier EHEC test was used to diagnose young adults impacted
by an outbreak of toxigenic E. coli in the state of Texas.
It has been determined that the bacteria Escherichia coli
(E. coli) strain O111 was the cause of illness in more than 52
individuals. Specimens were tested for E. coli O157:H7, the more
commonly-known form of E. coli, but produced a negative... |
| | | 07/12/99 | Meridian Type-Specific Herpes Tests Receive FDA Clearance to Market| CINCINNATI--(BW HealthWire)--July 12, 1999--Meridian Diagnostics,
Inc., Cincinnati, Ohio, (Nasdaq:KITS) today announced that it has
received clearance from the United States Food and Drug Administration
(FDA) to market two diagnostic tests for the herpes simplex virus.
These tests, Premier(TM) Type-Specific HSV-1 IgG ELISA Test and
Premier(TM) Type-Specific HSV-2 IgG ELISA Test, are the first medical
tests cleared by the FDA that have been proven to be able to
distinguish Herpes Simplex... |
| | | 07/07/99 | The Lancet Publishes Article on Meridian's HpSA Test for Stomach Ulcers| CINCINNATI--(BW HealthWire)--July 7, 1999--Meridian Diagnostics,
Inc., (Meridian) (Nasdaq:KITS) today announced that the esteemed
medical journal, The Lancet, published an article entitled, "Diagnosis
of Helicobacter pylori infection with a new non-invasive antigen-based
assay," (Dr. D. Vaira, et. al.). This article reports on a study
designed to confirm the accuracy of Meridian's Premier Platinum
HpSA(TM) (HPSA), the newly developed test for the detection of the
H. pylori antigen which ... |
| | | 06/29/99 | William J. Motto, CEO Of Meridian Diagnostics, Receives 1999 Entrepreneur of the Year Award| Business Editors, Health & Medical Writers
CINCINNATI--(BW HealthWire)--June 29, 1999--Meridian Diagnostics,
Inc., (Nasdaq:KITS), today announced that William J. Motto, Chief
Executive Officer, received The Cincinnati/Northern Kentucky 1999
Ernst & Young Entrepreneur of the Year Award in the Technology
division. This prestigious Award, given annually to owners and
managers, honors the area's entrepreneurs consisting of 26 total
finalists. ... |
| | | 04/21/99 | Meridian Diagnostics Announces Second Quarter and First Half Operating Results, Reports Profitable Operations At Gull Laboratories, and Declares Regular Cash Dividend| Business Editors, Health/Medical Writers
CINCINNATI--(BW HealthWire)--April 21, 1999--Meridian
Diagnostics, Inc. (Nasdaq:KITS) today announced net sales of
$14,654,000 for the second quarter of fiscal 1999 ended March 31,
1999, compared to net sales of $9,542,000 for the same period of the
prior fiscal year, an increase of $5,112,000, or 54%. Net earnings,
excluding the after-tax impact of merger integration costs of
$425,000 ($0.03 per ... |
| | | 01/28/99 | Meridian Announces Operating Results Including Record Sales for the First Quarter of Fiscal 1999| CINCINNATI--(BW HealthWire)--Jan. 28, 1999--Meridian
Diagnostics, Inc. (Nasdaq:KITS) today announced net sales for the
first fiscal quarter ended December 31, 1998 of $11,720,000, compared
to net sales of $8,448,000, during the same period of the prior fiscal
year. Net earnings, excluding the after-tax impact of one-time
restructuring and integration costs of $280,000 ($0.02 per share)
associated with the acquisition of Gull Laboratories on November 5,
1998, were $834,000 ($0.06 per share... |
| | | 12/29/98 | Quest Diagnostics Now Offers Meridian's New Premier Platinum HpSA -- Stomach Ulcer -- Test| CINCINNATI--(BW HealthWire)--Dec. 29, 1998--Meridian Diagnostics,
Inc., (Nasdaq:KITS) announced today that its Premier Platinum HpSA
(TM) stomach ulcer test is now available through Quest Diagnostics
Incorporated and its network of laboratories.
HpSA (Helicobacter pylori Stool Antigen), cleared for marketing
by the United States Food and Drug Administration (FDA) in May 1998,
is the first noninvasive direct test for H. pylori, the bacteria that
causes most stomach ulcers. A more recent ... |
| | | 12/22/98 | New Claims for Meridian Stomach Ulcer Test Cleared By FDA| CINCINNATI--(BW HealthWire)--Dec. 22, 1998--Meridian Diagnostics,
Inc., (Nasdaq:KITS) announced today that it has received clearance
from the United States Food and Drug Administration (FDA) to market
Premier Platinum HpSA(TM) (Helicobacter pylori Stool Antigen) to
monitor therapeutic response in patients with H. pylori infection.
Premier Platinum HpSA was initially cleared for marketing in May
1998 for diagnosis of H. pylori infection. H. pylori is the bacteria
that causes most stomach ... |
| | | 11/20/98 | Meridian Diagnostics, Inc. Declares Regular Quarterly Dividend and Comments on Dividend Policy| CINCINNATI--(BW HealthWire)--Nov. 20, 1998--The Board of
Directors of Meridian Diagnostics, Inc. (Nasdaq: KITS) announced
declaration of the resulting quarterly cash dividend of $0.05 per
share to be paid December 8, 1998 to shareholders of record on
November 25, 1998. The cash dividends paid and to be paid with regard
to the Company's fiscal 1998 operating results total approximately
$2,876,000 which represents a dividend payout ratio of 58%. Based on
the Company's fiscal 1998 ... |
| | | 11/13/98 | Meridian Diagnostics Announces Fourth Quarter and Fiscal Year-end Results| CINCINNATI--(BW HealthWire)--Nov. 13, 1998--Meridian Diagnostics,
Inc. (Nasdaq: KITS) , Cincinnati, Ohio, today announced net sales and
net earnings for the fourth fiscal quarter ended September 30, 1998 of
$6,952,000 and $853,000 ($.06 per share), respectively, as compared to
net sales and net earnings of $10,248,000 and $2,310,000 ($.16 per
share), respectively, during the same period of the prior fiscal year.
Net sales and net earnings for the fiscal year ended
September 30, 1998 ... |
| | | 11/06/98 | Meridian Diagnostics Completes Acquisition of Gull Laboratories and Implements Cost-Cutting Plans| CINCINNATI--(BW HealthWire)--Nov. 6, 1998--Meridian Diagnostics,
Inc., (Nasdaq: KITS) today announced the completion of the Gull
Laboratories, Inc. (AMEX: GUL) acquisition.
Gull common stock ceased trading at the close of business on the
American Stock Exchange on November 5, 1998. The transaction was
approved by a special meeting of the shareholders of Gull
Laboratories, held November 5, 1998. The former shareholders of Gull
Laboratories will receive $2.25 in cash for each common sh... |
| | | 10/02/98 | Meridian Diagnostics Announces Preliminary Fourth Quarter Results| CINCINNATI--(BW HealthWire)--Oct. 2, 1998--Meridian Diagnostics,
Inc., (Nasdaq: KITS) today announced, based on a preliminary review of
its operating results for the fourth quarter ended September 30, 1998,
that it expects net sales of approximately $7.0 million, down
approximately $3.0 million, over the same period of the prior fiscal
year. Net earnings are estimated to be in the range of $0.7 million to
$1.0 million as compared to $2.3 million for the fourth quarter of
fiscal 1997. Dilu... |
| | | 09/16/98 | Meridian Diagnostics and Gull Laboratories Execute Definitive Agreement to Merge| CINCINNATI--(BW HealthWire)--Sept. 16, 1998--Meridian
Diagnostics, Inc., (NASDAQ: KITS) today announced that it has entered
into a definitive agreement to acquire Gull Laboratories, Inc.
(ASE: GUL) through a merger transaction. The shareholders of Gull
Laboratories will receive $2.25 in cash for each common share.
Fresenius AG, the majority shareholder of Gull Laboratories, has
agreed, subject to certain conditions, to vote its Gull shares in
favor of the merger.
The transaction is ... |
| |
|
|
|
| |
